Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                       
Page - 1 -  
   TITLE PAGE  
 
 
Protocol  Title:  
A Randomized, Double -blind, Placebo -Controlled, Phase 3 Study to 
Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in 
Outpatients  with Mild to Moderate COVID -19 Illness  
 
 
Protocol Number:  GT0918 -US-3001  
Protocol Version : 2.0  
Amendment Number:  1 
Compound:  Proxalutamide (GT0918)  
Study Phase : 3 
Document Status: Final  
Release date:  08Jul2021  
Regulatory Agency Identifier  Number(s)  
IND:  154032  
EudraCT Number: 2021 -002153 -29 
 
 Confidential  Information  
The information provided herein contains Company trade secrets, commercial or financial 
information that the Company  customarily holds close and treats as confidential. The 
information is being provided under the assurance that the recipient  will maintain the 
confidentiality of the information under applicable statutes, regulations, rules, protective orders 
or otherwise . 
Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                       
Page - 3 -  
   INVESTIGATOR STATEMENT  
 
Protocol title:  A Randomized, Double -blind, Placebo -Controlled, Phase 3 Study to 
Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in 
Outpatients with Mild to Moderate COVID -19 Illness  
 
Protocol No.:  GT0918 -US-3001  
Version:  2.0 
The trial will be conducted in accordance with the ICH E6. The Principal Investigator 
will assure that no deviation from, or changes to the protocol will take place without 
prior agreement from the Sponsor  and documented approval from the Institutional 
Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to 
the trial subject s. All personnel involved in the conduct of this study have completed 
Human Subjects Protection Training.  
• I confirm agreement to conduct this study in compliance with the protocol.  
• I acknowledge that I am responsible for overall study conduct. I agree to 
personally conduct or supervise the described study.  
• I agree  to ensure  that all  staff members  involved  in the conduct  of this study  
are informed  about  their  obligations  in meeting  the above  commitments.  
 
Principal  Investigator:       
Print/Type  Name  
 
Signed:                
 
Signature Date:     
            (DD-MMM -YYYY)  
Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                       
Page - 4 -  
 ABBREVIATION S  
Term  Definition  
AACR  American Association for Cancer Research  
ACE2  Angiotensin Converting Enzyme 2  
ACVPU  Alert, Consciousness, Verbal, Pain, Unresponsive Scale  
AE Adverse Event  
ALT  Alanine Transaminase  
ANC  Absolute Neutrophil Count  
APTT  Activated Partial Thromboplastin Time  
AR Androgen Receptor  
ARDS  Acute Respiratory Distress Syndrome  
AST  Aspartate Transaminase  
ATC  Anatomical Therapeutic Chemical  
AUC  Area under the Curve  
BID Twice a Day  
BP Blood Pressure  
BMI  Body Mass Index  
CDC  Centers for Disease Control and Prevention  
CFR  Code of Federal Regulations  
CHO  Chinese Hamster Ovary  
CI Confidence Interval  
CIOMS  Council for International Organizations of Medical Sciences  
CK Creatinine kinase  
CLIA  Clinical Laboratory Improvement Amendments  
CMH  Cochran –Mantel –Haenszel  
CMP  Clinical Monitoring Plan  
CMS  Clinical Material Services  
CNS  Central Nervous System  
Cr Creatinine  
CR Complete Response  
CRF  Case Report Form  
CRO  Contract Research Organization  
CROMS  Clinical Research Operations and Management Support  
CRP  C-reactive Protein  
CRPC  Castrate Resistant Prostate Cancer  
COVID -19 Coronavirus Disease 2019  
CQMP  Clinical Quality Management Plan  
CSR  Clinical Study Report  
CTCAE  Common Terminology Criteria for Adverse Events  
DAIDS  Division of Allergy  and Infectious Diseases   
DCR  Disease Control Rate  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
Page - 5 -  
      DHHS  Department of Health and Human Services  
  
DMC  Data Monitoring Committee  
DMID  Division of Microbiology and Infectious Diseases  
DLT  Dose Limiting Toxicity  
DMP  Data Management Plan  
EC Ethics Committee  
ECOM  Extracorporeal Membrane Oxygenation  
EOS  End of Study  
EUA  Emergency Use Authorization  
FDA  Food and Drug Administration  
FiO2  Fraction of Inspired Oxygen in the Air  
FWA  Federal Wide Assurance  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practices  
hEGR  Human Ether -a-go-go-related Gene  
Hgb Hemoglobin  
HR Heart Rate  
IB Investigator’s Brochure  
IC50  A quantitative measure that indicates how much of a particular inhibitory 
substance (e.g., drug) is needed to inhibit, in vitro, a given biological 
process or biological component by 50%  
ICD International Classification of Diseases  
ICF Informed Consent Form  
ICH International Council for Harmonization  
ICU Intensive Care Unit 
IIT Institute Initiated Trial  
IND Investigational New Drug Application  
INR International Normalized Ratio  
iNOS  Inducible Nitric Oxide Synthase  
IRB Institutional Review Board  
IV Intravenous  
IWRS  Interactive Web Response System  
IxRS  Interactive Web/Voice Response System  
LLOQ  Lower Limit of Quantitation  
LNCaP  Lymph Node Carcinoma of the Prostate  
MCG  Microgram  
MedDRA  Medical Dictionary for Regulatory Activities  
MERS  Middle East Respiratory Syndrome  
MG Milligram  
MOP  Manual of Procedures  
MTD  Maximum Tolerated Dose  
N Number (typically refers to subjects)  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
Page - 6 -  
      NDA  New Drug Application  
NIAID  National Institute of Allergy and Infectious Diseases  
NIH National Institutes of Health  
NP Nasopharyngeal  
NOAEL  No Observed Adverse Effect Level  
NSAID  nonsteroidal anti -inflammatory drug  
OHRP  Office for Human Research Protections  
OP Oropharyngeal  
OTC  Over -the Counter  
PCR  Polymerase Chain Reaction  
PD Protocol Deviation  
PHI Protected Health Information  
PI Principal Investigator  
PLT Platelet  
PP Per Protocol  
PR Partial Response  
PSA  
Prostate -Specific Antigen  
PT Prothrombin Time  
QD Once A Day  
QT Interval  Measured from the Beginning of the QRS Complex to the End of the T 
wave  
QTc Corrected Q -T Interval  
RNA  Ribonucleic Acid  
RBC  Red Blood Cell  
RECIST  Response Evaluation Criteria in Solid Tumors  
RT-PCR  Reverse Transcription -Polymerase Chain Reaction  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SARS  Severe Acute Respiratory Syndrome  
SARS -CoV -2 Severe Acute Respiratory Syndrome Coronavirus 2  
SC Steering Committee  
SD Stable Disease  
SDCC  Statistical and Data Coordinating Center  
SDSP  Study Data Standardization Plan  
SMC  Safety Monitoring Committee  
SNP Single Nucleotide Polymorphisms  
SOA  Schedule of Activities  
SOC  System Organ Class  
SOP Standard Operating Procedure  
SpO2  Saturation of Peripheral Oxygen  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
T.Bili  Total Bilirubin  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
Page - 7 -  
      TEAE  Treatment Emergent Adverse Events  
TMPRSS2  Transmembrane Protease Serine 2  
TNF  Tumor Necrosis Factor  
ULN  Upper Limited Number  
UP Unanticipated Problem  
US United States  
WBC  White Blood Cell  
WHO  World Health Organization  
 
  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
Page - 8 -  
       
Sponsor Signature Page  ................................ ................................ ..........................  - 2 - 
Investigator Statement ................................ ................................ ............................  - 3 - 
Abbreviations  ................................ ................................ ................................ ..........  - 4 - 
Protocol Summary  ................................ ................................ ................................ ....... 1 
Synopsis  ................................ ................................ ................................ .....................  1 
Schedule of Activities (SoA)  ................................ ................................ ...................  11 
Amendment 1( 11-JUN -2021)  ................................ ................................ ........................   
1 ................................ ................................ ................................ .............   BACKGROUND
................................ ................................ ................................ ................................ ...... 15 
Overview of Disease Pathogenesis, Epidemiology, and Current Treatment  ...........  15 
Epidemiology ................................ ................................ ................................ ........  15 
Pathogenesis  ................................ ................................ ................................ .........  15 
Available Therapeutic Options in COVID -19 ................................ ......................  15 
Role of Androgen Receptor Antagoni st in COVID -19 ................................ ........  15 
Introduction to Investigational Treatment(s) ................................ ............................  16 
1.2.1 Overview of Proxalutamide (GT0918)  ................................ ........................  16 
1.2.2 Nonclinical Studies  ................................ ................................ ......................  17 
1.2.3 Cl inical Studies  ................................ ................................ ............................  20 
Risks and Benefits  ................................ ................................ ................................ .... 23 
1.3.1 Overall Benefit -Risk ................................ ................................ ....................  23 
1.3.2 Potential Benefits to Clinical Study Subjects  ................................ ..............  23 
1.3.3 Potential Risks to Clinical Trial Subjects  ................................ ....................  23 
2 ................................ ................................ ................................ ....................  RATIONALE
................................ ................................ ................................ ................................ ...... 24 
2.1  Study Rationale and Purpose ................................ ................................ ........  24 
2.2 Rationale for Study Design  ................................ ................................ ................  24 
2.3 Rationale for GT0918 Dose and Regimen Selection  ................................ .........  25 
2.4 Rationale for Choice of Comparator Drugs  ................................ .......................  25 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
Page - 9 -  
      3     OBJECTIVES AND ENDPOINTS  ................................ ................................ ... 26 
4  ................................ ................................ ................................ .............  STUDY DESIGN
................................ ................................ ................................ ................................ ...... 29 
4.1 Description of  Study Design  ................................ ................................ ..............  29 
4.1.1 Screening and Randomization  ................................ ................................ ..... 30 
4.1.2 Treatment Duration  ................................ ................................ ......................  31 
4.2 Timing of Interim Analyses and Design Adaptations  ................................ ........  31 
4.3 End of the study ................................ ................................ ................................ .. 31 
4.4 Early Study Termination  ................................ ................................ ....................  31 
5 ................................ ................................ ................................ .................  POPULATION
................................ ................................ ................................ ................................ ...... 32 
5.1 Patient Population  ................................ ................................ ..............................  32 
5.2 Inclusion Criteria  ................................ ................................ ................................  32 
5.3 Exclusion Criteria  ................................ ................................ ...............................  33 
6 ................................ ................................ ................................ ..................  TREATMEN T
................................ ................................ ................................ ................................ ...... 34 
6.1 Study Treatment  ................................ ................................ ................................ . 34 
6.1.1 Dosing Regimen  ................................ ................................ ..........................  34 
6.1.2 Guidel ines for Continuation of Treatment  ................................ ...................  35 
6.1.3 Ancillary Treatments  ................................ ................................ ...................  36 
6.1.4 Rescue Medication  ................................ ................................ ......................  36 
6.1.5 Treatment Duration  ................................ ................................ ......................  36 
6.2 Dose  Escalation  ................................ ................................ ................................ .. 36 
6.3 Dose Modifications  ................................ ................................ ............................  36 
6.3.1 Dose Discontinuation  ................................ ................................ ..................  36 
6.3.2 Follow -Up for Toxicities  ................................ ................................ .............  36 
6.3.3 Anticipated Risks and Safety Concerns of the Study Treatment  .................  36 
6.4 Concomitant Medications  ................................ ................................ ..................  37 
6.4.1 Permitted Concomitant Therapy  ................................ ................................ .. 37 
6.4.2 Prohibited Concomitant Therapy ................................ ................................ . 38 
6.4.3 Concomitant Therapy to Be Used with Caution  ................................ ..........  38 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
Page - 10 -  
      6.5 Patient numbering, Treatment Assignment or Randomization  ..........................  38 
6.5.1 Patient numbering  ................................ ................................ ........................  38 
6.5.2 Treatment Assignment or Randomization  ................................ ...................  39 
6.5.3 Treatment Blinding  ................................ ................................ ......................  39 
6.6 Study Treatment Supply  ................................ ................................ .....................  39 
6.6.1 Study Treatment Preparation and Dispensation  ................................ ..........  40 
6.6.2 Study Treatment Packaging and Labeling  ................................ ...................  40 
6.6.3 Drug Supply and Storage  ................................ ................................ .............  41 
6.6.4 Study Treatment Compliance and Accountability  ................................ ....... 41 
6.6.5 Disposal and Destruction  ................................ ................................ .............  41 
7 ................................ ................................ .VISIT SCHEDULE AND ASSESSMENTS
................................ ................................ ................................ ................................ ...... 42 
7.1 Study Flow and Visit Schedule  ................................ ................................ ..........  42 
7.1.1 Screening  ................................ ................................ ................................ ..... 42 
7.1.2 Treatment Pe riod ................................ ................................ .........................  43 
7.1.3 End of Treatment  ................................ ................................ ........................  44 
7.1.4 Withdrawal of Consent  ................................ ................................ ................  45 
7.1.5 Follow -Up for Safety Evaluations  ................................ ...............................  46 
7.1.6 Lost to Follow -Up ................................ ................................ .......................  46 
7.1.7 End of Safety Follow -Up ................................ ................................ .............  47 
7.2 Assessment  ................................ ................................ ................................ .........  47 
7.2.1 Efficacy Assessments  ................................ ................................ ..................  47 
7.2.2 Safety and Tolerability Assessments  ................................ ...........................  49 
7.2.3 Pharmacokinetics  ................................ ................................ .........................  52 
7.2.4 Biomarkers ................................ ................................ ................................ ... 52 
7.2.5 Polymerase Chain Reaction (PCR)  ................................ ..............................  52 
7.2.6 Patient Reported Outcomes  ................................ ................................ .........  53 
7.2.7 Virology  ................................ ................................ ................................ ....... 53 
7.2.8 Development of resistance ................................ ................................ ...........  53 
8. SAFETY MONITORING AND REPORTING  ................................ ...................  55 
8.1 Adverse Events  ................................ ................................ ................................ ... 55 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
Page - 11 -  
      8.1.1 Definitions and Reporting  ................................ ................................ ...........  55 
8.1.2 Events NOT Meeting the AE Definition:  ................................ ....................  56 
8.1.3 Laboratory Test Abnormalities  ................................ ................................ .... 57 
8.2 Adverse Events of Special Interest (AESI)  ................................ ........................  58 
8.3 Serious Adverse Events  ................................ ................................ ......................  58 
8.3.1 Definitions  ................................ ................................ ................................ ... 58 
8.3.2 SAE Reporting  ................................ ................................ .............................  58 
8.4 Suspected Unexpected Serious Adverse Reactions (SUSARs)  .........................  59 
8.5 Emergency Unblinding of Treatment Assignment ................................ .............  60 
8.6 Pregnancies ................................ ................................ ................................ .........  60 
8.7 Warnings and P recaution  ................................ ................................ ...................  61 
8.8 Independent Data Monitoring Committee (IDMC)  ................................ ...........  61 
8.9 Steering Committee  ................................ ................................ ............................  62 
9. DATA COLLECTION AND MANAGEMENT  ................................ .................  63 
9.1 Data Confidentiality  ................................ ................................ ...........................  63 
9.2 Site Monitoring  ................................ ................................ ................................ .. 63 
9.3 Data Collections  ................................ ................................ ................................ . 63 
9.4 Database Management  ................................ ................................ .......................  64 
9.5 Qualit y Control  ................................ ................................ ................................ ... 64 
10. STATISTICAL METHODS AND DATA ANALYSIS  ................................ .... 65 
10.1 General Considerations  ................................ ................................ ....................  65 
10.2 Analysis Sets  ................................ ................................ ................................ .... 65 
10.2.1 Intent -to-Treat Analysis Set (ITT)  ................................ .............................  65 
10.2.2 Modified Intent -to-Treat Analysis Set (mITT)  ................................ ..........  65 
10.2.3 Safety Analysis Set (SS)  ................................ ................................ ............  65 
10.2.4 Per -Protocol Analysis Set (PPS) ................................ ................................  65 
10.2.5 Pharmacokinetic Analyses  ................................ ................................ .........  65 
10.3 Subject Demographics/Other Baseline Characteristics  ................................ .... 66 
10.4 Treatments (Study Treatment, Concomitant Therapies, Compliance)  .............  66 
10.5 Efficacy Analysis  ................................ ................................ .............................  66 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
Page - 12 -  
      10.5.1 Primary Efficacy Objective  ................................ ................................ ....... 66 
10.5.2 Secondary Objectives Variables  ................................ ................................  68 
10.6 Exploratory Objectives  ................................ ................................ .....................  71 
10.6.1 Pharmacokinetics of GT0918  ................................ ................................ .... 71 
10.6.2 Viral resistance to GT0918  ................................ ................................ ........  71 
10.7 Safety Analysis  ................................ ................................ ................................ . 72 
10.7.1 Analysis set and grouping for the analyses  ................................ ...............  72 
10.7.2. Adverse events  ................................ ................................ ..........................  72 
10.7.3 Laboratory abnormalities  ................................ ................................ ...........  72 
10.7.4 Other safety data  ................................ ................................ ........................  73 
10.8 Interim Analysis  ................................ ................................ ...............................  73 
10.9 Sample Size Calculation ................................ ................................ ...................  74 
11. . ETHICAL CONSIDERATIONS  AND ADMINISTRATIVE PROCEDURES
................................ ................................ ................................ ................................ ...... 75 
11.1 Regulatory and Ethical Compliance  ................................ ................................ . 75 
11.2 Responsibilities of the Investigator and IRB/IEC/REB  ................................ ... 75 
11.3 Informed Consent Procedures  ................................ ................................ ..........  76 
11.4 Discontinuation of the Study  ................................ ................................ ............  76 
11.5 Publication of Study Protocol and Results  ................................ .......................  76 
11.6 Study Documentation, Record Keeping and Retention of Documents  ............  77 
11.7 Source Documents ................................ ................................ ............................  77 
11.8 Confidentiality of Study Documents and Subject Records  ..............................  77 
11.9 Audits and Inspections  ................................ ................................ .....................  78 
11.10 Financial Disclosures  ................................ ................................ .....................  78 
12. PROTOCOL ADHERENCE  ................................ ................................ ..............  79 
13. REFERENCES  ................................ ................................ ................................ ..... 80 
14.APPENDICES  ................................ ................................ ................................ ....... 81 
Appendix 1. Drugs that Should Be Used Cautiously with GT0918 .........................  81 
Appendix 2. Common COVID -19-Related Symptoms ................................ ............  83 
Appendix 3 COVID -19:  ................................ ................................ ..........................  85 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
Page - 13 -  
      BASELINE SEVERITY CATEGORIZATION (Developing Drugs and Biological 
Products for Treatment or Prev ention Guidance for Industry )  ...............................  85 
Appendix 4 Clinical Laboratory Parameters Collection Plan  ................................ .. 87 
Appendix 5. Subject Questionnaire  ................................ ................................ ..........  89 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
1 
 PROTOCOL SUMMARY  
Synopsis  
Protocol Title:   
A Randomized, Double -blind, Placebo -Controlled, Phase 3 Study to 
Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in 
Outpatient s with Mild to Moderate COVID -19 Illness . 
Short Title:  A Phase 3 Study to Evaluate the Efficacy and Safety of GT0918 in  
Outpatients with Mild to Moderate COVID -19 Illness  
Protocol Number:  GT0918 -US-3001  
Study Phase:  3 
Sponsor:  Suzhou Kintor Pharmaceuticals, Inc.  
Rationale:  
Coronavirus disease 2019 (C OVID -19) emerged in late 2019 and spread rapidly, 
resulting in a global pandemic. New COVID -19 cases and deaths have been 
constantly rising. COVID -19 is caused by a novel coronavirus (SARS -CoV -2), and 
infected persons can have a wide range of disease severity, with many patients 
showing mild or moderate disease.  Althoug h many therapies have been and are being 
explored in various stages of COVID -19, for the large population with mild and 
moderate COVID -19, limited treatments are available. There is a huge unmet medical 
need for home -use, oral intake , treatments for mild t o moderate COVID -19 patients to 
ameliorate symptoms and prevent hospitalization.  
Much research has proven that SARS -CoV -2 cell entry and fusion depends on 
angiotensin converting enzyme 2 (ACE2) and transmembrane protease serine 2 
(TMPRSS2). In humans, andr ogens are the only known transcription promoters for 
the TMPRSS2 gene. Further, the ACE2 receptor, also critical for SARS -CoV -2 viral 
infectivity, is affected by male sex hormones with higher activity found in males. So , 
androgen receptor antagonist s have the potential to reduce virus entry and viral 
infectivity.  
Proxalutamide (GT0918) , a new investigational androgen receptor (AR) antagonist  
with more specificity and activity in inhibiting androgen receptors , has shown to 
inhibit the expression of ACE2 and TMPRSS2 in lung epithelial cells. GT0918 can 
also down -regulate the protein expression level of inflammation -related factor 
inducible nitric oxide synthase (iNOS) and the mRNA expression level of iNOS and 
tumor necrosis factor (TNF). Recent research showed that GT0918 inhibited SARS -
CoV -2 infection  more effectively than Enzalutamide in LNCaP cells in a dose -
dependent manner, with concentration that inhibits response by 50% (IC50) values of 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
2 
 97 nM . Further more,   the preclinical results suggest that GT0918  should more 
effectively inhibit AR -dependent expression of ACE -2 and TMPRSS2 than 
Enzalutamide in a variety of SARS -Cov2 infected organs, including lung, 
Gastrointestinal (GI), heart, and kidney.  
The clinical s tudy of GT0918 treatment in Brazil for COVID -19 outpatients 
([STUDY_ID_REMOVED]) showed the hospitalization rate was significantly decreased in the 
GT0918 group compared with placebo group  (0 vs . 27% in the male cohort and 3 
vs.19% in the female cohort ). No serious adverse event  (SAE) occur red in the 
GT0918  group  compared with 27% in the placebo group  in the male cohort . In the 
female cohort, t he percentage of subjects reported to have SAEs was 3%  in the 
GT0918  group  and 19% in the placebo group . 
GT0918  will be administered to  evaluate its effect in accelerating recovery following  
SARS -CoV -2 infection , limiting spread  into lung cells,  improv ing the clinical 
outcome and reduc ing hospitalization in COVID -19 infected outpatients with mild or 
moderate sympto ms. 
Objectives and Endpoints:   
Objectives  Endpoints  
Primary    Primary  
To evaluate the efficacy  in terms  of 
clinical status following treatment 
with GT0918 compared to placebo  Percentage of subjects who  do not experience any of the 
following events  due to all causes by Day  28: 
• Hospitalization for ≥ 24 hours or  
• Supplemental oxygen for ≥24 hours  in response to 
SpO2 ≤93% or 
• Death  
Secondary   Secondary  
 •  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
3 
 To evaluate the clinical efficacy of 
GT0918 compared to placebo  
using the NIAID 8 - point scoring 
scale  Percentage of subjects achieving each clinical 
status by Days 7, 14 and 28 as defined below based 
on The National Institute of Allergy and Infectious 
Diseases (NIAID) 8- point scoring scale : 
1 Death  
2 Hospitalized, on invasive mechanical ventilation 
or extracorporeal membrane oxygenation 
(ECMO)  
3 Hospitalized, on non -invasive ventilation or 
high flow oxygen devices  
4 Hospitalized, requiring supplemental oxygen  
5 Hospitalized, not requiring supplemental oxygen 
- requiring ongoing  medical care (COVID -19-
related or otherwise)  
6 Hospitalized, not requiring supplemental oxygen 
- no longer requires ongoing medical care  
7 Not hospitalized, limitation on activities and/or 
requiring home oxygen  
8 Not hospitalized, no limitations on activities  
To evaluate the clinical efficacy of 
GT0918 compared to placebo  
based on clinical status  • Proportion of subjects with all -cause hospitalization 
(defined as ≥24 hours) by Day 28  
• Proportion of subjects h ospitaliz ed (defined as ≥24 
hours) due to COVID -19 related events by Day 28  
• Days of hospitalization due to all cause s or COVID -
19 
• Proportion of subjects with a ll-cause mortality by 
Day 28 
• Proportion of subjects with COVID -19 related 
mortality by Day 28  
• Proportion of subjects admitted to an ICU due to 
COVID -19 by Day 28  
• Days in intensive care unit  (ICU)  
• Proportion of subjects requiring supplemental 
oxygen, high-flow oxygen, any  ventilation or 
ECMO due to COVID -19 by Day 28  
• Proportion of subjects requiring mechanical 
ventilation or ECMO due to COVID -19 by Day 28  
• Days on supplemental oxygen/high flow oxygen 
devices/mechanical ventilation  
•  
Characterize the effect of GT0918 
compar ed to placebo on symptom 
improvement or resolution  Symptom Improvement:  
• Change in symptom score (total of ratings) from 
baseline to  Days 3, 7, 14 and 28  
• Time to symptom improvement  
• Proportion of subjects demonstrating symptom 
improvement via the symptom questionnaire (total 
of ratings)  on Days 3, 7, 14 and 28  
Symptom resolution:  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
4 
 • Proportion of subjects demonstrating symptom 
resolution via the symptom questionnaire on Days 
3, 7, 14 and  28 
• Time to symptom resolution  
Characterize the effect of GT0918 
compared to placebo on 
SARS -CoV -2 viral load clearance  • Change from baseline to Days 3, 7, 14 and 28 in SARS -
CoV -2 viral load  
• Proportion of subjects that achieve SARS -CoV -2 
clearance (Days 3, 7, 14 and 28)  
• Time to SARS -CoV -2 clearance  
• SARS -CoV -2 viral load area under the 
concentration -time curve (AUC) assessed  to days 3, 7, 
14 and 28  
Characterize the effect of GT0918 
compared to placebo on safety  Safety assessments such as AEs , SAEs  and laboratory data  
Exploratory  Exploratory   
Characterize the pharmacokinetics 
of GT0918  • Mean trough concentration of GT0918 and GT0955 on 
Days 1, 3, 7 and 14  
• To explore relationships between GT0918 and/or 
GT0955 exposure and selected efficacy and safety 
endpoints and/or biomarkers  
Characterize emergence of viral 
resistance to  GT0918  Screening for novel mutants in subjects  who do not 
respond to GT0918  
• Genotype of SARS -CoV -2 viral isolates  
To explore biomarkers predictive of  
GT0918 safety, efficacy, and/or 
disease progression and COVID -19 
clinical outcomes  
  • The association between changes in disease related 
biomarkers with clinical endpoints  
Study Design  
Overall Design:  
This is a Phase 3, randomized, double -blind, placebo -controlled, multicenter study to 
evaluate the safety and efficacy of Proxalutamide (GT0918) in adult outpatients 
diagnosed with mild to moderate COVID -19. 
The population of subjects with mild to moderate  COVID -19 illness will be chosen to 
evaluate if anti -androgen therapy may effectively prevent progression to the severe 
form of COVID -19 illness by treating this population early in their disease course and 
prior to respiratory compromise and failure.  
This study utilizes an adaptive design that maximizes efficiency in identifying a safe 
and efficacious therapeutic agent for COVID -19 during the current outbreak. The 
study is a multicenter trial that will be conducted in the United States ( US) and other 
coun tries. Approximately 668 subjects  will be randomized in a 1:1 ratio to either 
GT0918 or placebo. There will be one interim analysis . The interim analysis will be 
conducted when 334 subjects complete Day 28 after first dose.  The blood samples for 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
5 
 population (pop) PK analysis need to be collected for at least 100 subject s, whom will 
also be randomized into the interventional treatment or placebo group with 1:1 ratio.  
Randomization:  
Subjects will be randomized into 1 of 2 arms w ith 1:1 ratio, each will receive an 
interventional treatment  or placebo  with standard of care . 
Randomization will be stratified by:  
• Sex: Male or Female  
• Race and ethnicity (non -Hispanic White or other  /Hispanic or Latino /non -
Hispanic Black)  
• Number of risk factors  0, 1-2, ≥3 (based on CDC defined conditions )   
Study Duration  
The subject will remain on study treatment up to 14 days. 14-day post treatment period 
with a post treatment visit on Day 28. The safety follow -up will be up to 28  days after 
last dose  making the overall duration of monitoring 42 days for each subject . 
End of Study  
A subject is considered to have completed the study  if he has completed all require d 
phases of the study including the last scheduled procedure shown in the Schedule of 
Activities (SoA).  
The end of the study is defined as the date of last scheduled procedure shown in the 
SoA for the  last enrolled subject or last ongoing subject in the study , whichever comes 
later.  
Inclusion Criteria  
Subjects are eligible to be included in the study only if  all the following criteria apply:  
1. The subject or legally authorized representative give signed informed consent 
which includes compliance with the requirements and restrictions listed in the 
ICF and in this protocol.  
2. Understand and agree to comply with pl anned study procedures . 
3. Male and non -pregnant female  subjects with age ≥18 years of age at the time of 
randomization . 
4. Are currently not hospitalized . 
5. Have one or more COVID -19-related symptoms within 5 days of onset of 
symptoms onset (FDA COVID -19-Related symptom guidance , See Appendix 
2, available at: https://www.fda.gov/media/142143/download ) 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
6 
 6. Must have firs t positive SARS -CoV -2 viral infection determination (has 
laboratory -confirmed SARS -CoV -2 infection as determined by PCR, or other 
commercial or public health assay in any specimen) ≤3 days prior to start of the 
first dose .  
7. Women of child -bearing potential , defined as all women physiologically 
capable of becoming pregnant, unless they are using highly effective 
contraception, as shown below, throughout the study and for 3 months after 
stopping GT0918 treatment. Highly effective contraception methods include :  
• Total Abstinence (when this is in line with the preferred and usual 
lifestyle of the patient. Periodic abstinence (e.g. calendar, ovulation, 
symptothermal, post -ovulation methods) and withdrawal are not 
acceptable methods of contraception, or   
• Use of one of the following combinations (a+b or a+c or b+c):   
a: Use of oral, injected or implanted hormonal methods of 
contraception or other forms of hormonal contraception that have 
comparable efficacy (failure rate < 1%), for example hormone vaginal 
ring or transdermal hormone contraception.   
b: Placement of an intrauterine device (IUD) or intrauterine system 
(IUS);  
c: Barrier methods of contraception: Condom or Occlusive cap 
(diaphragm or cervical/vault caps) with spermicidal 
foam/gel/film/cream/vaginal supp ository;  
• Female sterilization (have had prior surgical bilateral oophorectomy with 
or without hysterectomy) or tubal ligation at least six weeks before taking 
study treatment. In case of oophorectomy alone, only when the 
reproductive status of the woman has been confirmed by follow -up 
hormone level assessment;  
• Male sterilization (at least 6 months prior to screening). For female 
subject s on the study, the vasectomized male partner should be the sole 
partner for that subject ; 
In case of use of oral contraception women should have been stable for a 
minimum of 3 months before taking study treatment. Women are considered 
post-menopausal and not of childbearing potential if they have had 12 months 
of natural (spontaneous) amenorrhea with an appropri ate clinical profile (e.g. 
age appropriate, history of vasomotor symptoms) or have had surgical 
bilateral oophorectomy (with or without hysterectomy) or tubal ligation at 
least six weeks ago. In the case of oophorectomy alone, only when the 
reproductive st atus of the woman has been confirmed by follow up hormone 
level assessment, is she considered not of childbearing potential;  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
7 
 8. Regardless of their fertility status, male subjects must agree to either remain 
abstinent (if this is their preferred and usual lif estyle) or use condoms as well 
as one additional highly effective method of contraception (less than 1% failure 
rate) or effective method of contraception with nonpregnant women of 
childbearing potential partners for the duration of the study and until 90 days 
after the last dose.  
9. Agree to the collection of nasopharyngeal swabs and venous blood . 
Exclusion Criteria  
Subjects are excluded from the study if any of the following criteria apply:  
1. Have SpO 2 ≤ 93% on room air at sea level or PaO 2/FiO 2 < 300, respiratory  rate 
≥30 per minute, heart rate ≥125 per minute (FDA resource page,  COVID -19: 
Developing Drugs and Biological Products for Treatment or Prevention 
Guidance for Industry (fda.gov) ). 
2. Estimated glomerular filtration rate (eGFR) < 30 ml/min  
3. Serum total bilirubin > 1.5 x ULN (upper limit of normal)  and AST and ALT >3 
x ULN  
4. Subjects with significant cardiovascular disease  as followi ng: 
i. heart failure NYHA class ≥3 
ii. left ventricular ejection fraction <50%  
iii. those with a history of cardiac arrhythmias, including long QT syndrome.  
5. Has been admitted to a hospital prior to randomization, or is hospitalized 
(inpatient) at  randomiza tion, due to COVID -19 or requires treatment with 
supplemental oxygen.  
6. Have known allergies to any of the components used in the formulation of the 
interventions . 
7. Have hemodynamic instability requiring use of vasopressors within 24 hours 
of randomization . 
8. Suspected or proven serious, active bacterial, fungal, viral, or other infection 
(except COVID -19) that in the opinion of the investigator could constitute a 
risk when taking intervention ( i.e. known history of human immunodeficiency 
virus [HIV]). 
9. Have any  co-morbidity requiring surgery within <7 days, or that is considered 
life-threatening  within 30 days. 
10. Have any serious concomitant systemic disease, condition, or disorder that, in 
the opinion of the investigator, should preclude participation in this stu dy.  
11. Subjects  with myopath y. 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
8 
 12. Prior, current, or planned future use of any of the following treatments: COVID -
19 convalescent plasma, mAbs against SARS -CoV -2, IVIG (any indication) , 
where prior use is defined as the past 30 days or less than 5 half-lives of the 
investigational product (which is longer) from screening.  
13. Have participated, within the last 30 days, in a clinical study involving an 
investigational intervention. If the previous investigational intervention has a 
long half -life, 5 half -lives or 30 days, whichever is longer, should have passed.  
14. Are concurrently enrolled in any other type of medical research judged not to 
be scientifically or medically compatible with this study.  
15. Subject taking an anti -androgen of any type including androgen depravation 
therapy, 5 -alpha reductase inhibitors, etc. within 3 months before dosing . 
16. Are investigator site personnel directly affiliated with this study . 
Investigational and Reference therapy  
For this study, investigational drug (study drug) refers to Kintor study drug  
Proxalutamide  (GT0918) . GT0918 will be supplied by Kintor or its designee as 
100 mg tablets as individual patient supply packaged in blister . 
• Arm 1: Subjects administered GT0918 , 200 mg q.d . after regular conventional 
meal  plus standard of care for 14 consecutive days  
• Arm 2: Subjects administered GT0918 , matched  placebo q.d. after regular 
conventional meal  plus standard of  care for 14 consecutive  days  
The dose should be given the same time each day (+/ - 2 hours for medication  
scheduling).  
Any dose that is delayed may be given later that calendar day. Any dose that is missed 
(not given that calendar day) is not made up. The treatment co urse should continue as 
described above even if the subject becomes SARS -Cov-2 test negative  or 
experiences complete resolution of symptoms .  
All subjects may be treated according to standard of care simultaneously, and 
medications may be part of the treat ment paradigm. The study treatment refers to the 
study drug/placebo plus standard of care.  Dose escalation is not applicable  in this 
study.  
For the subjects who develop Grade 3 or 4 adverse events (AEs) , suspected to be 
drug-related by the investigator, the study drug administration should be discontinued. 
This subject will enter post-treatment  period  with the safety follow -up up to 28 days 
after last lose . There is no dose interruption or reduction in thi s study.  
Safety Assessment  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
9 
 • Safety assessments will include the incidence, and severity of AEs and laboratory 
abnormalities graded per Division of Allergy  and Infectious Diseases (DAIDS) 
Table for Grading the Severity of Adult and Pediatric Adverse  Events, version 2.1 
(July 2017) . 
• Safety  evaluation s will be performed per SoA during the study.  
• The assessments, as described in Section 7.2.2 , will occur at baseline, Days 3, 7, 
14 and 28 or early withdraw al visit following randomizations  (+/-2 days). The 
information will be recorded in the appropriate eCRF.  
• Subjects will receive safety evaluation at regular visits as specified in the 
procedures, including physical examination, vital signs, laboratory tests. In 
addition, ECGs, chest X-ray, and CT -scan could be done per the investigator’s 
discretion.  
• In addition to scheduled visits in the protocol, unscheduled visits may be 
conducted as appropriate based on the subject `s AEs  or clinical status.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
10 
 Statistical c onsiderations:  
Sample size calculation  
The primary endpoint event rate for the treatment arm is assumed at 97% and for the 
placebo arm is assumed at 9 1%.  
The sample size was calculated using EAST v6.5  software  for a group sequential test 
for 2  proportions. With a total of 668 subjects the study will have 90% power at a 
one-sided 0.025 significance level of the hospitalization or death rate using a Chi -
square test with one interim analysis at 50% of the informat ion (when 334 subjects 
have been observed for 28 days) . 
Statistical analysis : 
The primary endpoint event rate will be compared between treatment and placebo arm 
using Cochran –Mantel –Haenszel (CMH) chi-square  test using the stratification 
factors at time of  randomization at the one-sided 0.0 25 level based on modifi ed 
Intent -to-Treat ( mITT).  
An interim analysis will be conducted when 334 subjects complete Day 28 after first 
dose. An independent data  monitoring committee ( IDMC) will review the interim 
analysis report to conclude early efficacy, make recommendations about early study 
closure, change study population, or change to study sample size.  
If the one-sided p-value is less than 0.00 15, the stopping boundary for effica cy is met 
and the study could be stopped for efficacy.  
Analysis Set s 
The intent -to-treat analysis set (ITT)  includes all randomized subjects . 
The mITT set will include all randomized subjects who have received at least one 
dose of study  medication .  
The safety analysis set (SS) includes all subjects with at least one dose of study  
medication  and will be analyzed as treated .  
The Per -Protocol Analysis Set (PP) includes all mITT subjects without major protocol 
violations  which will be defined under classification specification prior to unblinding 
of the study treatment code.  
The Pharmacokinetic Analyses (PK) will be conducted on data from at least 100 
subjects who receive intervention and have evaluable PK.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
11 
 Schedule of Activities (SoA)  
Assessments obtained previously as part of routine clinical care may be used as the screen assessment if they were done no  more 
than one day  before randomization. Visits may be conducted as a te lephone call, outpatient clinic or home visit, if  the protocol SoA 
is followed and in compliance with local regulatory.   
Table 1 Schedule of Activities  
  Screen  Treatment Period  Early 
Withdrawal 
19 Post-treatment  Safety 
Follow 
Up 20 
Study Day (Visit Window ±  
days)  D-1 D1 D3 D7 (± 1)  D14 
(+1)  (+2) D15 D28 
(± 2) D42 
Phone 
Call 
(± 2) 
Informed Consent  X                 
Inclusion/Exclusion Review 1 X                 
Demographics 2 X                 
Preexisting Conditions and 
Medical History 3 X                 
NIAID Ordinal Scale4  X Daily    
Prior Treatment 5 X                 
Tobacco Use  X                 
Physical Examination 6 X Symptom Directed PE only if Clinical Indicated    
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
12 
 Vital Signs 7 X   X X X X   X   
Nasopharyngeal swabs 8 X   X X X X   X   
Randomization 9 X X               
Hematology 10 X   
  X X X   X   
Chemistry 10 X   
  X  X X   X   
Biomarkers 10  X   X   X X   X   
Coagulation 10 X       X X   X   
Drugs and Diary Dispense 11 X X               
GT0918 or Placebo 
Administration 11   Daily from D1 to D14          
Subject D iary 11  Daily from D1 to D14          
Questionnaire (Symptoms ; 
Overall Clinical Status ; ) 11 Daily    
Chest X -ray or CT Scan 12 Clinical ly Indicated    
12-ECG 12 Clinical ly Indicated    
Hospitalization events 13   Daily  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
13 
 Clinical status and 
concomitant procedures if 
subject is hospitalized 14   Daily if hospitalized  
Adverse Events 15 X 
Concomitant Medications 16 X 
Pharmacokinetics  17   X X X X         
Pregnancy test18 
X       X  
COVID -19 vaccination status  
X         
 
 
Annotation:  
1. Inclusion/Exclusion review: every subject needs to meet all inclusion and exclusion criteria. The eligibility checklist needs  to be signed by the investigator or 
sub-investigator.  
2. Demographics: includes age, gender, race, and ethnicity . 
3. Pre-existing condi tions and medical history: obtained from interview or available information and including timing of exposure and onset of symptoms 
suggestive  of SARS -CoV -2 infection.  
4. NIAID ordinal scale to be completed daily through Day 28 or 14 days after last dose. This  information can be collected from questionnaire; reported events; 
or directly from the patient.  
5. Prior treatments within last 30 days.  
6. Physical exam (PE): Full physical exam should be done at screening visit. For the subsequent visits, symptom directed PE can be done per investigator’s 
discretion. If the result is clinically significant, the PE result should be recorded in eCRF.  
7. Vital sign: documentation of hospital -based exam is acceptable. Vital signs include body temperature, pulse rate, systolic and di astolic blood pressure, 
respiratory rate. For screening visit, SpO 2, and supplemental oxygen flow rate, FiO 2 if known and method of delivery if applicable , also need to be recorded.  
Record blood pressure and SpO 2 while subject is at rest.  
8. Nasopharyngeal (NP) swabs: Only  NP swab sample is acceptable.  The method of taking samples should be consistent for each  subject during the whole 
period of this study . This does not need to be the same before screening visit, when the subject is first time  confirmed SARS -CoV -2 positive at local 
laboratory and/or Point of Care testing . Sample for first positive test must be collected within 3 days prior to start of dosing. Local laboratory and/or Point of 
Care testing are acceptable.  
9. Randomization: randomiza tion should be via the Interactive Voice/Web (IxRS) Response System. Randomization should be done after confirm ation the 
subject meet s all inclusion/exclusion criteria. Drugs and Diary Dispense should occur after randomization. It is allowed for the subjec t to take the drug on the 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
14 
 same day of the screening visit after confirmation of eligibility and randomization ( the screening visit is counted as D1 too ). The Subject Diary should start 
to be complete d.   
10. Laboratory tests: Hematology, Chemistry  (including C reatinine Kinase), Biomarkers (including Procalcitonin, C -reactive protein, D -dimer, Ferritin, 
Troponin , Testosterone ), Coagulation . For details refer to Section 7.2.2  and 7.2.4 .  
11. GT0918 or placebo administration: GT0918 or placebo will be given orally once daily on Days 1 -14 during the study period after  a meal (± 2 hours for 
medication scheduling). The drug taken time should be recorded with subject diary. If the screening day is also D1, the subje ct does not need to follow the 
drug taken window on screening day/D1. For d etails refer to Section 6.1 . 
Subject Diary should be completed every day since first dose  until the last dose.  
Questionnaire should be completed every day since screening visit to the end of post -treatment  by Day 28 . For d etails refer to Section 7.2.6 .  
12. Chest X -ray or CT -Scan or 12 -ECG can be done per investigator’s discretion. If investigator deems the result is clinically significant, the result should be 
recorded with eCRF.  
13. Hospitalization events: if the su bject is hospitalized, the treatment may be continued to the 14 days per PI. Hospitalization is defined as ≥24 hours in hospital 
of care . For d etails refer to Section 7.1. 2. 
Record if the following events occur:  
• Emergency room visits  
• Hospitalized  
• ICU admittance  
• Discharge  
• Extended care facility admittance (refers to long term care for chronic diseases or prolonged rehabilitation, which is not defined as hospitalization)  
14. Documentation from hospital records is acceptable.  
Includes:  
• Limitation on activities due to COVID - 19 
• Ongoing hospital medical care  
• Supplemental oxygen  
• Non-invasive ventilation or high flow oxygen device  
• Mechanical ventilation  
• ECMO, or  
15. Adverse events: any events that occur after signing the informed consent are considered AEs as defined in Section 10.3 . 
16. Concomitant medications: all medications administered within 30 days prior to the fi rst dose of study treatment through 30 days after the last dose of study 
treatment will be recorded in the concomitant medications, for details refer to Section 6.4 .  
17. Pharmacokinetics (PK) samples only need t o be taken for at least  100 subjects, who will be assigned according. For details refer to Section 7.2.3 . 
18. All women regardless of childbearing potential must complete a serum pregnancy test at screening visit, urinary pregnancy test on day 28  as per the schedule 
of assessment  for women of childbearing potential . Local laboratories will be used for the analysis of serum and urinary pregnancy test s. 
19. Early wi thdraw al (EW): if the subject is early withdrawn from this study for any reason ( Section  7.1.4 ), the subject should complete the EW visit, and the 
visit should occur within 2 days of the EW day. The subject will go t o the safety follow -up period for additional 28 days after his last dose.   
20. D42 (or 28 days ± 2 post last dose if subject is withdraw n early ) safety follow -up visit is phone call visit.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
15 
 1  BACKGROUND  
Overview of Disease Pathogenesis, Epidemiology, and Current Treatment  
Epidemiology   
Coronavirus disease 2019 (Covid -19) emerged in late 2019 and spread rapidly, resulting in a 
global pandemic. New COVID -19 cases and deaths have been constantly r ising.  As of 
20 December 2020 , there have been over 75 million cases and over 1.6 million deaths since the 
start of the pandemic.  In the US, the overall cumulative COVID -19-associated hospitalization 
rate through the week ending 05 December 2020, was 278.7  hospitalizations per 100,000 
population. ( CDC  weekly summary).  
Pathogenesis  
COVID -19 is caused by a novel severe acute respiratory syndrome coronavirus 2  (SARS -CoV -
2), and infected persons can have a wide range of disease severity, with many subject s showing 
asymptomatic , mild or moderate  disease . In severe and critical cases, it results in progressive 
pulmonary infection, complicated by respiratory failure, with a high prev alence of acute 
respiratory distress syndrome. According to data from China, 81% of people with C OVID -19 
had mild or moderate disease, 14% had severe disease, and 5% had critical illness （3）. 
Two main processes are thought to drive the pathogenesis of COVID -19. Early in the course of 
the infection, the disease is primarily driven by replication of SARS -CoV -2. Later in the course 
of infection, the disease is driven by an exaggerated immune/infla mmatory response to the virus 
that leads to tissue damage ( NIH Therapeutic Management of Patients with COVID -19). 
Available Therapeutic Options in COVID -19  
Although many therapies have been and are being explored in various stages of COVID -19, for 
the lar ge population with mild and moderate COVID -19, limited treatments are available. B y 
December  2020,  the FDA had issued an emergency use authorization  (EUA)  to only 2 
treatments : Bamlanivimab  given alone , as well as Casirivimab and Imedevimab  given together  
for the treatment of mild to moderate COVID -19, which could work against the SARS -CoV -2 
spike protein to reduce viral replication . However,  both EUA -issued treatments are monoclonal 
antibodies and require IV injection. Therefore, there is a  huge unmet medical need  for home -use, 
oral intake , treatment s for mild to moderate COVID -19 patient s to ameliorate symptoms and 
prevent hospitalization .  
Role of Androgen Receptor Antagonist in COVID -19 
SARS -CoV -2 encodes nonstructural and structural proteins required for its viral life cycle. 
Among them, the spike glycoprotein plays a pivotal role in SARS -CoV -2 infection by 
recognizing and attaching to ACE2 transmembrane protein on host cells. The spike protein is 
also cleaved and activate d by cell surface TMPRSS2 to facilitate membrane fusion and entry.  It 
has been confirmed that targeting the expression or activity of ACE2 or TMPRSS2 play s a 
critical role in the pathogenicity of coronavirus infection. I n mice models, inhibiti on of 
TMPRSS2 function can decrease the SARS -CoV -2 entry into lung cells and similar observation 
was shown in the inhibition of ACE2 function  (5).   
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
16 
 Further more , it has become clear that there is a gender disparity in severity of COVID -19 with 
males having higher hospitalization and mortality rates  than females.  
However, elevated testosterone level has also been observed in most female COVID -19 subject s 
(Maria Schroeder 2020) , and there wa s a positive correlation between testosterone levels and 
pro-inflammatory cytokines in female COVID -19 subject s. 
The data have show n that treatment with an antiandrogen  reduces TMPRSS2  in human lung cells 
dramatically decreased TMPRSS2  levels in the lungs of mice  (1). To determine therapeutic 
potential, the authors  assessed uptake of live SARS -CoV -2 into human lung cells and saw a 
signi ficant reduction in viral  entry and infection upon treatment with an antiandrogen . Together 
with striking c o-expressi on of AR and  TMPRSS2 in specific  lung cell types that are targeted by 
SARS -CoV -2., these  data provide strong evidence to support clinical trials to assess the efficacy  
of antiandrogens as a  treatment option for COVID -19. 
 
Introduction to Investigational Treatment( s) 
1.2.1 Overview of Proxalutamide (GT0918)  
Compound Name: Proxalutamide Tablet (GT0918)  
Chemical Name:  
4-[4,4-dimethyl -3-[6-[3-(2-oxazolyl) propyl ]-3-pyridinyl] -5-oxo-2-thioxo -1-imidazolidinyl] -3-
fluoro -2-(trifluoromethyl) -benzonitrile  
 
Chemical Structure  
 
 
 
Molecular Formula: C 24H19F4N5O2S 
Molecular Mass: 517.50 g/mol  
Dosage Form: Tablet (100  mg) 
GT0918 is a new investigational second -generation  AR antagonist with more specificity and 
activity in inhibiting androgen receptors. GT0918 demonstrates a dual mechanism of action in 
cell assays: inhibiting the binding of androgen to AR as well as exhibiti ng pharmacological 
effects of inducing the downregulation  of AR expression （2）. 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
17 
 1.2.2 Nonclinical Stud ies 
1.2.2.1 Nonclinical Pharmacology  
In vitro studies, GT0918 demonstrates a dual mechanism of action, i.e., highly effective in 
inhibiting the binding of androgen to AR as well as exhibiting pharmacological effects of 
inducing the downregulation  of AR expression, while bicalutamide and enzal utamide did not 
affect AR level in the same study, GT0918 also down -regulated AR protein level in tumors in a 
dose-dependent manner  (4). 
1.2.2.2  Anti -tumor Activity in Xenograft Models  
GT0918 is also effective in blocking AR signaling in breast cancer cell s expressing AR. In an 
anti-proliferation assay, it selectively inhibited the growth of AR+ breast cancer cells such as 
MCF -7 and MDA -MB-453 while demonstrated no effects toward AR - breast cancer cells such as 
MDA -MB-231 and MDA -MB-468. Furthermore, GT0918  demonstrated excellent anti -tumor 
effectiveness in nude mice AR+ breast cancer xenograft tumor models including MCF -7 model 
and BT474 model. GT0918 did not significantly affect the body weight of animals. The optimal 
effective dose in nude mice was 10 - 20 mg/kg (QD). The in vivo anti -tumor efficacy was better 
than that of enzalutamide at lower or equal dose.  
GT0918 demonstrated the dose -dependent anti -tumor effectiveness in nude mice xenograft 
tumor models. GT0918 did not significantly affect the body weight of animals and effectively 
suppressed the elevation of PSA. The optimal effective dose in nude mice was 20 mg/kg (BID). 
The in vivo efficacy was si milar to that of enzalutamide but required much lower drug exposure 
than enzalutamide .  
GT0918 is also effective in blocking AR signaling in breast cancer cells expressing AR. In an 
anti-proliferation assay, it selectively inhibited the growth of AR+ breas t cancer cells such as 
MCF -7 and  MDA -MB-453 while demonstrated no effects toward AR - breast cancer cells such as 
MDA -MB-231 and MDA -MB-468. Furthermore, GT0918 demonstrated excellent anti -tumor 
effectiveness in nude mice AR+ breast cancer xenograft tumor m odels including MCF -7 model 
and BT474 model. GT0918 did not significantly affect the body weight of animals. The optimal 
effective dose in nude mice was 10 - 20 mg/kg (QD). The in vivo anti-tumor efficacy was better 
than that of enzalutamide at lower or equ al dose.  
1.2.2.3 Safety Pharmacology and Toxicology   
An in vitro cardiovascular safety pharmacology study for human ether -a-go-go-related gene 
(hERG ) channel inhibition in CHO cells showed that GT0918 was a very weak hERG -mediated 
potassium channel blocker, with an IC50 much higher than 10 μM. This strongly suggests that 
the potential for QT prolongation at clinically relevant concentrations by GT0918 is low. In 
addition, no evidence of QTc prolongation was observed in the cardiovascular and respiratory 
safety pharmacology study in conscious Beagle dogs after oral administration at doses up to 
50 mg/kg.  
The maximum tolerated dose (MTD) was 500 mg/kg in  the acute animal study, and the no 
observed adverse effect level (NOAEL) was 60 mg/kg after GT0918 orally administered to 
Sprague Dawley rat s for 28 days. In Beagle dogs, the MTD and NOAEL were 2000 mg/kg and 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
18 
 50 mg/kg, respectively, in the acute and the 2 8-day study. The adverse effect noted in rat and dog 
studies were reversible during the 4 -week recovery period. No seizure or convulsion was 
observed in animals throughout the general toxicology studies including high doses in acute 
studies as well as repe at dosing studies.  
No significant changes in CNS function were observed with GT0918 in rats at doses up to 
180 mg/kg. GT0918 did not produce adverse effects on cardiovascular functions, respiratory 
functions,  and the body temperature in conscious beagle do gs after oral administration at doses 
up to 50 mg/kg.  
Altogether, these findings with high doses of GT0918 in animal were benign . When choosing a 
dose for start of clinical studies in humans, algorithms were used to choose a lower dose at which 
these find ings would be absent or minimized.  
1.2.2.4 Drug Metabolism and Pharmacokinetic  
In vitro  studies to establish the metabolite profiles of GT0918 were performed in multiple animal 
species including mouse, rat, dog, monkey, and human. Drug metabolism and pharmacokinetic 
studies were also perfor med in vivo  in rats and dogs.  
Chemical inhibitor in human live microsomal incubation indicate CYP3A4 was the major 
cytochrome P450 enzyme responsible for the formation of major metabolites of GT0918 in 
human liver microsomes.  LC-MS/MS results showed that GT0918 showed no significant 
inhibition on CYP1A2 and  CYP2E1, weak inhibition on CYP2D6, CYP2C9, CYP2C19 and 
CYP3A (midazolam), but marked inhibition on CYP3A4 (testosterone).  Therefore, the inhibitory 
effect of GT0918 on CYP3A4 in vitro  and the corresponding in vivo  drug interaction potential 
needs to be fu rther investigated.  
1.2.2.5  GT0918 Effect  on TMPRSS2 and ACE2  Expression  
The spike glycoprotein plays a pivotal role in SARS -CoV -2 infection by recognizing and 
attaching to ACE2 transmembrane protein on host cells. The spike protein is also cleaved and 
activated by cell surface TMPRSS2 to facilitate membrane fusion and entry. GT0918  has shown 
to inhibit  protein  expression of ACE2 and TMPRSS2 induced by androgen -AR activation in 
prostate and lung epithelial cells . 
 
 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
19 
  
 
Figure 2. The protein levels of AR, ACE2 and TMPRSS2 in LNCaP  (left) and A549  (right)  
cells with the indicated  treatment were determined by western blotting . 
GT0918  was also showed to  inhibit  macrophage activation markers  iNOS and TNF -α expression  
induced by Lipopolysaccharide  in macrophage cells . These results suggested that GT0918 could 
inhibit the pathogen -induced macrophage activation . 
 
 
 
Figure 3 Relative expression of iNOS in RLE -6TN cells with the indicated treatment was 
determined by Quantitative PCR.  
Recently, u sing this SARS -CoV -2 bioassay platform, we demonstrated that Proxalutamide more 
effectively inhibited SARS -CoV -2 infection than Enzalutamide in LNCaP cells in a dose -
dependent manner, with concentration that inhibits response by 50% (IC50) values of 97 nM . 
We have also compared the effect of Proxalutamide with  Enzal utamide on the expression of 
androgen receptor (AR), ACE2 and TMPRSS2 in an AR overexpressing/androgen independent 
prostate cancer cell line C4 -2B at the concentration of 12.5µ M  (data on file) . The results showed 
that proxalutamide more effectively inhibit ed the expression of AR, ACE -2 and TMPRSS2 than 

  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
20 
 Enzalutamide in C4 -2B cells. These results suggest that GT0918  should more effectively inhibit 
AR-dependent expression of ACE -2 and TMPRSS2 than Enzalutamide in a variety of SARS -Cov2 
infected organs, includi ng lung, GI, heart, and kidney.  
 
1.2.3 Clinical  Studies  
1.2.3.1 Clinical Studies in Solid Tumors  
Four clinical studies  are ongoing in both China and the US and 3 studies conducted both in 
China and in US have been completed  in prostate cancer and breast cancer .  
1.2.3.1.1 Completed Clinical Studies  in Solid Tumors  
GT0918 -US-1001  
The US study  is a Phase I/II open -label, non -randomized, dose escalation, 2 -part, study in 
subjects with metastatic castrate resistant prostate cancer ( mCRPC ) who progressed after both 
hormonal therapy (abiraterone or enzalutamide) and chemotherapy (docetaxel), or who could not 
tolerate either or both therapies. The finished Phase 1 part (GT0918 -US-1001 ) was a multiple 
dose-escalation evaluation to establish safety and tolerability of GT0918.  Total of 40 subjects 
were enrolled into this study  at 7 dose levels : 50 mg  (n=3) , 100 mg  (n=6) , 200 mg  (n=6) , 300 mg  
(n=7) , 400 mg  (n=7) , 500 mg  (n=6)  and 600 mg (n=5). Of the 40 subject s in the GT0918 -US-
1001 study, 39 (98%) experienced at least 1 treatment -emergent adverse events (TEAE ) during 
the study, with the most frequent A Es being fatigue, nausea, decreased appetite, anemia, weight 
decrease, diarrhea, constipation, back pain,  and dizziness. Most of subject s reported TEAEs that 
were considered related to the study drug, with the most common drug -related A Es being fatigue 
(42.5%), decreased appetite (20%), nausea ( 15%), dizziness (12.5%), constipation (12.5%), 
anemia (10%), weight decrease (10%), dysgeusia (10%), and diarrhea (7.5%). Most TEAEs were 
Grade 1 or 2. Twenty subject s across all dose cohorts reported TEAEs of Grade 3  or higher. 
Each individual TEAE of Grade 3 or higher occurred sporadically in 1 or 2 subject s, except for 
the following: anemia (7/40), fatigue (5/40) and sepsis (3/40). The majority of Grade 3 or higher 
TEAEs were considered not related to the study drug . All serious adverse events ( SAEs ) and 
Grade 3 or higher A Es were reported across all dose cohorts. The majority of SAEs and Grade 3 
or higher A Es, as well as 2 deaths, were due to disease progression and were not related to the 
study drug, except for one  event of Grade 4 increased creatine phosphokinase (CK).  
Overall, GT0918 was generally well tolerated in mCRPC subject s who had progressed after 
multi -lines of hormone therapies and chemotherapies. No DLT was reported and MTD was not 
established. No partia l response ( PR) or complete response ( CR) was observed in the study. 
Clinical responses of stable disease ( SD) were observed and used for decision on -treatment 
continuation. Dose levels of 400 and 500 mg/day were chosen for the Phase 2 study  to further 
establish the safety and tolerability of GT0918.  
GT0918 -CN-1001 
The GT0918 -CN-1001 study was a Phase 1 study, conducted in China, to investigate safety, 
tolerability, and pharma cokinetics of GT0918 in subject s with advanced CRPC. Nineteen 
subject s were enrolled,  and 16 subject s were treated with GT0918 at f5 dose levels: 50 mg (n 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
21 
 = 2), 100 mg (n = 4), 200 mg (n = 3), 300 mg (n = 3) and 400 mg (n = 4). GT0918 showed some 
prelimina ry anti -tumor activity. No DLT  was observed. The MTD was not reached. All the 
GT0918 -related adverse events (AEs) were Grade 1, including hypercholesterolemia, 
hyperglyceridemia, anemia, hot flush, fatigue, constipation, and loss of appetite. All subject s 
who received GT0918 showed some preliminary anti -tumor activity with SD (bone scans 
showed no change in target and non -target lesions comparing with baseline).  
GT0918 -CN-1003  
The GT0918 -CN-1003 was an open -label, randomized, Phase 2, multicenter s tudy to evaluate 
the safety and efficacy in subject s with mCRPC.  Total of 108 subject s were  enrolled in the study  
and randomized in 1:1:1 ratio in to 100 mg, 200  mg and 300 mg cohorts:  100 mg  (n=37 ), 200 mg 
(n=35 ) and 300 mg  (n=36 ). Eighty -one subject s (75.0%) experienced ≥grade 1 drug -related 
AEs. Fourteen subject s (13.0%) experienced ≥ Grade 3 A Es based on CTCAE v4.03. Most 
common drug -related A Es experienced ≥10% of subject s included aspartate aminotransferase 
increased (AST) (14.8%), alanine  aminotransferase increased  (ALT)  (13.0%), white blood cell 
count decreased (12.0%), appetite decreased (13.0%), asthenia (17.6%), anemia  (14.8%) and 
proteinuria (12.0%).  Grade 3 asthenia, Grade 2 vomiting, Grade 2 hypokalemia , Grade 2 lung 
infection, Grade 3 anemia  were the reported SAEs among all subject s. There were  about 41.9% 
subject s who experienced Prostate -Specific Antigen  (PSA) 50 reduction . Based on Response 
Evaluation Criteria in Solid Tumors (RECIST ) 1.1 evaluation, the Overall Response Rate ( ORR ) 
was 15.8% and Disease Control Rate (DCR ) was 78.9%.  
1.2.3.1.2 Ongoing Clinical Studies  in Solid Tumors  
GT0918 -US-1002  
The ongoing GT0918 -US-1002 study was an open -label randomized, expanded/phase 2 study in 
subjects with metastatic hormone sensitive prostate cancer (mHSPC) or mCRPC who progressed 
after either Abiraterone or Enzalutamide treatment to further evaluate the safety, tolerability,  and 
anti-tumor activity of once daily orally administered GT0918.  
GT0918 -CN-1004  
A Phase 3, multicenter, randomized, double -blind, placebo -controlled study is being conducted to 
evaluate the efficacy and safety of GT0918 in subject s mCRPC who progressed after both 
Abiraterone and Docetaxel in China. Subject s in the GT0918 cohort or control cohort received 
GT0918/placebo tablets 200 mg QD until radiographic progression , unacceptable toxicity,  or 
withdrawal from the study.  
GT0918 -CN-1005  
A Phase 3, multicenter, randomized double -blind study to evaluate the efficacy and safety of 
GT0918 in combination with Abiraterone vs Placebo plus Abiraterone as first -line treatment i n 
subjects  with mCRPC in China. This two -stage study consisted of a dose -finding stage followed 
by a dose -expansion stage.  
GT0918 -CN-2001  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
22 
 A Phase 1/1b study is being conducted to assess the safety, tolerability, and pharmacokinetics of 
GT0918 in subject s with advanced breast cancer. This two -stage study consisted of a dose -
escalation stage followed by a dose -expansion stage. All subject s received oral GT0918 once daily  
until disease progression, unacceptable toxicity, or withdrawal from the study.  
1.2.3.2 Clinical Study in COVID -19 
A randomized, double -blinded, clinical study of GT0918  was done  in Brazil for both male and 
female subjects with mild or moderate COVID -19 illness ([STUDY_ID_REMOVED]) . Two hundred and 
sixty -two (262) men were included in the study . 134 men were assigned to the GT0918  group and 
128 men were assigned to the control group. The mean age was 44.5± 7.7 years old. Thirty -five 
subjects  (27%) were hospitalized in the control group compared to 0 patient s in the GT0918  group  
by Day 30 . The proportion of COVID -19 subject s hospitalized was significantly different between 
the GT0918  and control arms; p <0.0001. No subject  receiving GT0918  died compared to 2% in 
the control group. Additionally, it also showed a clinical meaningful SARS -Cov-2 viral load 
reduction and clearance in the GT0918  group compared to the placebo group (RT -PCR positive 
rate: 42.5% vs 93.8% on Day 7, 15.0% vs 56.2% on Day 14 and 10.0% vs 4 3.8% on Day 28, 
respectively) .   
Treatment -emergent adverse events were reported for 34% of subjects in the  GT0918  group  and 
for 61% of subjects in the placebo group . SAEs were only reported  in the placebo group. There 
was no AE leading to discontinuation.  
The most frequently reported TEAEs (occurring in ≥10% of subjects) were diarrhea (21%), 
dehydration (15%), nausea (14%), abdominal pain (12%), dyspepsia  (11%) and back pain (10%) 
in the GT0918  group. The most frequently repo rted TEAE were disease pro gression (54%), fatigue 
(45%), shortness of breath (36%), fever (20%), dehydration (14%), anosmia (13%), ageusia (12%), 
back pain (12%), and ear pain (10%) in the placebo group. Gastrointestinal TEAE were more 
frequent in the GT09 18 group. General, respiratory, and nerve system TEAEs are more frequent 
in the placebo group.  The TEAEs suspected  to be related with study treatment  (≥10%) were 
diarrhea, nausea, abdominal pain and dyspepsia in the GT0918  group. No SAE was reported in the  
GT0918  group. Acute respiratory distress syndrome was reported as SAE in 27% of the subjects 
in the placebo group.  
178 female subjects were randomized to the study  with 76 in the GT0918 group and 102 in the 
control group. All subjects were also treated wi th the standard of care.  
The mean age was 44.2 years old. Nineteen  subjects  (19%)  were hospitalized in the control group 
compared to 2 patients  (3%)  in the GT0918  group  by Day 30  . (p<0.0001 ). No subject  receiving 
GT0918  died compared to one (1 %) in the control group.  
Treatment -emergent adverse events were reported with 36% of subjects in the GT0918 group and 
with 55% of subjects in the placebo group . TESAEs were reported with 3% and 19% of subjects 
in the  GT0918 and placebo groups respectively.   
Gastrointestinal TEAE were more frequent in the GT0918 group   compared with the control group: 
Diarrhea (17% vs. 10%), Nausea (12% vs. 6%), Abdominal pain (12% vs 5%), Dyspepsia (12% 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
23 
 vs. 4%). Therefore, GT0918 may be an excellent treatment option to improve  the clinical outcomes 
and reduce the hospitalization for COVID -19 infected patients.  
Risks and Benefits  
1.3.1 Overall Benefit -Risk  
GT0918 dosed at 200  mg once daily has shown remarkable  activity for accelerating  SARS -Cov-
2 clearance  and decreasing the hospitalization rate significantly in subjects  with mild to moderate 
COVID -19 illness. The clinical ly meaningful benefit combined with the clinically manageable 
safety profile of GT0918 strongly support a positive benefit -risk balance for treatment of 
COVID -19 subjects . 
1.3.2 Potential Benefits to Clinical Study  Subject s 
All subjects  with COVID -19 mild/moderate illness  enrolled in this study will be randomized to 
receive GT0918  or placebo  plus standard of care . The efficacy of GT0918  seen in the IIT study 
(NCT 04446429 ) is highly encouraging in patients with mild or moderate C OVID -19 illness. 
Based on preclinical and preliminary clinical data  (Section 1.2.2  and 1.2.3 ), treatment with 
GT0918  is expected to be well tolerated and it is hypothesized that it will result in preventing 
disease progression by decreasing the expression of ACE2 and TMPRSS2  and prevent ing SARS -
CoV -2 entry into lung cells . 
1.3.3 Potential Risks to Clinical Trial Subject s 
The safety profile of GT0918  is manageable . The adverse events identified with GT0918 
treatment in COVID -19 were gastrointestinal AEs, including diarrhea, nausea, abdominal pain 
and dyspepsia . 
In the study for subject s with C OVID -19, there were no treatment related AEs or serious AEs 
during the course of the study.  
Subject s in this study will be carefully monitored for key toxicities that have been observed with 
GT0918  with the following assessments:  periodic laboratory, renal, and liver function, and 
coagulation . Risk will be further minimized by adherence to inclusion/exc lusion criteria, 
avoidance of prohibited medication, close safety monitoring and dose modification guidelines. 
An independent data committee (IDMC) will be constituted and will monitor safety, efficacy as 
outlined in the protocol. A steering committee (SC)  will be established comprising of 
investigators and Kintor personnel participating in the study  to ensure transparent management 
of the study  according to the protocol. A Kintor/delegated CRO safety management team will 
periodically review and evaluate al l emerging data across the GT0918  program for potential 
safety signal assessment in a timely manner.  
Furthermore, due to the short treatment duration ( 14 days) of 200  mg once a day, the risk of SAE s 
should be lower than completed  and ongoing studies in onc ology.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
24 
 2 RATIONALE  
2.1  Study Rationale and Purpose  
The glycoprotein spikes on the surface of SARS -CoV -2 utilize membrane ACE2 receptors and  
TMPRSS2, to enter the host cells  (6). Thus , targeting the expression or activity of ACE2 or 
TMPRSS2 plays a critical role in reducing the pathogenicity of coronavirus infection, GT0918  
can down -regulate the ACE2 and TMRPSS2 expression in prostate, lung cancer cell  lines and 
lung epithelial cell  lines. Furthermore, the clinical study of GT0918  in Brazil for COVID -19 
([STUDY_ID_REMOVED]) showed a clinical ly meaningful SARS -CoV -2 viral load reduction and 
clearance , decreased the hospitalization rate significantly in  the GT0918 group compared to the 
placebo  group . Therefore, GT0918 may be an efficient option to improve clinical outcome  and 
reduce the rate of hospitalization in COVID -19 infected patients.  Since SARS -CoV -2 replication 
is greatest just before or soon after symptom onset, GT0918  is likely to be most effective when 
used early.  Therefore, in this study, GT0918  will be administered to evaluate the efficacy and 
safety in COVID -19 infected outpatients  with mild or moderate symptoms . 
2.2 R ationale for Study Design  
This is a randomized , placebo -controlled two -arm study with the objective to evaluate the 
efficacy and safety of GT0918  in outpatients  with mild or moderate COVID -19 illness. The 
study is designed per FDA guidance ( COVID -19: Developing Drugs and Biological Products for 
Treatment or Prevention Guidance for Industry (fda.gov) ). 
The randomized, double -blind, placebo -controlled, multicenter, parallel group design is  the gold 
standard for a phase III study  as it minimizes allocation bias, balancing both known and 
unknown prognostics factors in the assignment of treatments.  The study is stratif ied by  sex, race 
and ethnicity,  the risk factors of COVID -19 severity  (Section 4.1.1 ) The study will be conducted 
in outpatients including  subjects with underlying medical conditions such as the elderly, underlying 
cardiovascular or respiratory disease, diabetes, chronic kidney d isease, or other comorbidities.  Both 
male and female subjects are being studied in line with the anti -androgenic mechanism of action , 
since elevated testosterone level has also been observed in most female COVID -19 subjects, and 
a positive correlation betw een testosterone levels and pro -inflammatory  cytokines  in female 
COVID -19 subjects  (Maria Schroeder 2020) . 
The trial will ensure to include Hispanic , Latino non -Hispanic  black, and others  from United 
states and other countries . 
The study drug GT0918 is  evaluated in randomized, placebo -controlled, double -blind clinical studies  
using a superiority design.  A futility analysis will be done for initial assessment of potential benefit 
before enrolling a large number of subjects.  
IDMC will be used to ensure subject safety and study  integrity . 
The standard of care is accepted  in both arms  which is described in Section 6.4 .  
The primary endpoint  is the percentage of subjects who  do not experience all-cause 
hospitalization for at least 24 hours, do  not require supplemental oxygen for at least 24 hours in 
response to SpO2 ≤93% and are alive by Day 28. . Considering the incapability to hospitalize 
the subjects who meet the criteria of hospitalization , the supplemental oxygen requirement 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
25 
 provided outside  for equal to or longer than 24 hours  in response to SpO2 ≤93% is also 
considered as the hospitalization . All-cause death by day 28 will also be included.  
Proportion of patients alive , non -hospitalized and free of  oxygen  is generally considered an 
adequate composite study endpoint to measure clinical improving . Defining hospitalization as  
requiring  greater than or equal 24 hours in patient care within 28 days of randomization eliminate s 
the majority of  patients who might attend  hospital for reasons other than deterioration to severe 
disease or for necessary management of their condition.  
According to FDA guidance, the 28-day time frame  of endpoint is appropriate  in the outpatient 
treatment trial .  
The primary efficacy analysis will be conducted in the mITT  population .  
The secondary endpoints include the  symptom improvement, symptom resolution, NIAID 8 -
point scoring scale, all-cause and COVID -19 related hospitalization, mechanical ventilation, 
viral load reduction and clearance at specific time points during the study  and are designed to 
monitor response to GT0918  in terms of other important clinical and virological outcomes.  
In addition,  Ctrough values will be monitored to establish exposure -response relationship of 
GT0918 in the treatment of SARS -CoV -2. The  relevant biomarkers analysis will also be 
performed to evaluate their  association with observed clinical responses to GT0918  and the 
disease state .    
2.3 Rationale for GT0918  Dose and Regimen Selection  
A dose of 200 mg was recommended based on a phase 2 study in prostate cancer with 28 days as 
a cycle, until disease progres sion. Fourteen  days is used in this study to align with the standard 
time course of COVID -19. Based on available preliminary data from Brazil IIT study in subject s 
with COVID -19 mild/moderate illness, 200  mg, QD  for 15 days has been demonstrated  to be  
effective  and display ed adequate  safety in the treatment  of COVID -19. Therefore, almost  the same 
dose regimen is being used in this study with the same patient population  as was used in the 
Brazilian study . 
2.4 Rationale for Choice of Comparator Drugs  
Subject s enrolled in this study will either be mild or moderate COVID -19 who are not hospitalized . 
There are no approved treatment options for this patient population except an EUA for the 
investigational monoclonal antibody therap y. Bamlanivimab  alone or C asirivimab and 
Imedevimab  given together  or Bamlanivimab and etesevimab given  in combination for the 
treatment of  mild-to-moderate COVID -19 in adult and pediatric patients.  Therefore , place bo 
comparator  was selected , however, best supporti ve therapy/standard of care  except those are 
prohibited in Section 6.4.2 can be administered in both treatment and control groups as required 
at the investigator’s discretion.  
  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
26 
 3     OBJECTIVES AND ENDPOINT S 
Objectives  Endpoints  
Primary    Primary  
To evaluate the efficacy in terms of 
clinical status  following treatment 
with GT0918 compared to placebo  Percentage of subjects who do not experience any of the 
following events  due to all causes  by Day 28:  
• Hospitalization for ≥ 24 hours  
• Supplemental oxygen for ≥24 hours  in response to 
SpO2 ≤93%  
• Death  
Secondary   Secondary  
To evaluate the clinical efficacy of 
GT0918 compared to placebo 
using the NIAID 8 - point scoring 
scale  Percentage of subjects achieving each clinical 
status on Days 7, 14 and 28 as defined below based 
on The National Institute of Allergy and Infectious 
Diseases (NIAID) 8 - point scoring scale:  
1 Death  
2 Hospitalized, on invasive mechanical ventilation 
or ext racorporeal membrane oxygenation 
(ECMO)  
3 Hospitalized, on non -invasive ventilation or 
high flow oxygen devices  
4 Hospitalized, requiring supplemental oxygen  
5 Hospitalized, not requiring supplemental oxygen 
- requiring ongoing medical care (COVID -19-
related or otherwise)  
6 Hospitalized, not requiring supplemental oxygen 
- no longer requires ongoing medical care  
7 Not hospitalized, limitation on activities and/or 
requiring home oxygen  
8 Not hospitalized, no limitations on activities  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
27 
 To evaluate the clinical efficacy of 
GT0918 compared to placebo 
based on clinical status  • Proportion of subjects with all -cause hospitalization 
(defined as ≥24 hours) by Day 28  
• Proportion of subjects hospitalized (defined as ≥24 
hours) due to COVID -19 related events by Day 28  
• Days of hospitalization due to all causes  or COVID -
19 
• Proportion of subjects with all -cause mortality by 
Day 28 
• Proportion of subjects with COVID -19 related 
mortality by Day 28  
• Proportion of subjects admitted to an ICU  due to 
COVID -19 by Day 28  
• Days in intensive care unit (ICU)  
• Proportion of subjects requiring supplemental 
oxygen, high-flow oxygen, any ventilation or 
ECMO due to COVID -19 by Day 28  
• Proportion of subjects requiring mechanical 
ventilation or ECMO due to COVID -19 by Day 28  
• Days on supplemental oxygen/high flow oxygen 
devices/mechanical ventilation  
Characterize the effect of GT0918 
compared to placebo on symptom 
improvement or resolution  Symptom Improvement:  
• Change in symptom score (total of ratings) from 
baseline to  Days 3, 7, 14 and 28  
• Time to symptom improvement  
• Proportion of subjects demonstrating symptom 
improvement via the symptom questionnaire (total 
of ratings)  on Days 3, 7, 14 and 28  
Symptom resolution:  
• Proportion of subjects demonstrating symptom 
resolution via the symptom questionnaire on Days 
3, 7, 14 and 28  
• Time to symptom resolution  
Characterize the effect of GT0918 
compared to placebo on 
SARS -CoV -2 viral load clearance  • Change from baseline to Days 3, 7, 14 and 28 in SARS -
CoV -2 viral load  
• Proportion of subjects that achieve SARS -CoV -2 
clearance (Days 3, 7, 14 and 28)  
• Time to SARS -CoV -2 clearance  
• SARS -CoV -2 viral load area under the 
concentration -time curve (AUC) assessed  to days 3, 7, 
14 and 28  
Characterize the effect of GT0918 
compared to placebo on safety  Safety assessments such as AEs, SAEs and laboratory data  
Exploratory  Exploratory   
Characterize the pharmacokinetics 
of GT0918  • Mean trough concentration of GT0918 and GT0955 on 
Days 1, 3, 7 and 14  
• To explore relationships between GT0918 and/or 
GT0955 exposure and selected efficacy and safety 
endpoints and/or biomarkers  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
28 
 Characterize emergence of viral 
resistance to  GT0918  Screening for novel mutants in patients who do not respond 
to GT0918  
• Genotype of SARS -CoV -2 viral isolates  
To explore biomarkers predictive of  
GT0918 safety, efficacy, and/or 
disease progression and COVID -19 
clinical outcomes  
 The association between chan ges in disease related 
biomarkers with clinical endpoints  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
29 
 4  STUDY DESIGN  
4.1 Description of Study Design  
This is a Phase 3, randomized, double -blind, placebo -controlled, multicenter study to evaluate 
the safety and efficacy of Proxalutamide (GT0918) in adult outpatients diagnosed with mild to 
moderate COVID -19. The study will be 2 -arm comparison against matched placebo. The study 
will be conducted in around 100 sites in the USA and other  countries.  
This study utilizes an adapti ve design that maximizes our efficiency in identifying a safe and 
efficacious therapeutic agent for COVID -19 during the current outbreak. There will be an interim 
analysis after 334 subjects complete Day 28 after the first dose to allow early stopping for 
futility, efficacy, or safety.  
The study population will be subjects with mild to moderate COVID -19 illness chosen to 
evaluate if early intervention with anti -androgen therapy prior to respiratory compromise can 
effectively prevent progression to the sever e form of COVID -19 illness.  
Randomization is essential for establishing efficacy of these new therapeutic agents.  
The blood samples for PK analysis need to be collected for at least 200 subjects , whom will also 
be randomized into the interventional treatm ent or placebo group with 1:1 ratio.  
Schema  
 
Figure 4: Study GT0918 -US-3001 schema.  
 
 

  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
30 
 4.1.1 Screening and Randomization  
After signing the study ICF, the screening assessments will be done within 1 day prior to 
randomization for selected assessments (See SoA) for the list of assessments to be performed).  
The investigator will review symptoms, risk factors and other inclusion  and exclusion criteria to 
confirm subject’s eligibility.  
Subjects will be randomized into 1 of 2 arms with 1:1 ratio, each will receive an interventional 
treatment/placebo.  
Randomization will be stratified by the following factors:  
• Sex: Male or Female  
• Race and ethnicity (non -Hispanic White or others /Hispanic or Latino /non -Hispanic 
Black)  
• Number of risk factors  0, 1-2, ≥3 (based on CDC defined conditions  
https://www.cdc.gov/coronavirus/2019 -ncov/need -extra -precautions/people -with-
medical -conditions.html ). Adults with the following conditions  are at increased risk  of 
severe illness from the virus that causes COVID -19: 
o Age ≥ 65 years  
o Cancer  
o Chronic kidney disease  
o Chronic lung diseases, including COPD (chronic obstructive pulmonary disease)  
asthma (moderate to severe),interstitial lung disease, cy stic fibrosis, and 
pulmonary hypertension  
o Dementia or other neurological conditions  
o Down Syndrome  
o Heart conditions, such as heart failure, coronary artery disease, or 
cardiomyopathies  or hypertension  
o Immunocompromised state (weakened immune system) from so lid organ 
transplant  
o Liver disease  
o Overweight and Obesity (body mass index [BMI] ≥25 kg/m2) 
o Sickle cell disease  or thalassemia  
o Smoking , current or former  
o Diabetes  Type 1 or type 2)   
o HIV infection  
o Solid organ or blood stem cell transplant  
o Stroke or cerebrovascular disease, which affects blood flow to the brain  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
31 
 o Substance use disorders  
o Others  per most updated list from CDC  website  as above  
 
4.1.2 Treatment Duration  
Subject will receive  treatment for 14  days, Day 1 to Day 14 . Fro m screening  visit Day -1 to visit 
Day 28 ± 2 days  post last treatment  which corresponds to Day 42  Safety Follow -up visit . The 
scheduled procedure shown in the Schedule of activities (SoA)   
 
4.2 Timing of Interim Analyses and Design Adaptations  
The ongoing study may be modified based on planned interim analyses. Based on the observed 
data at the time of the interim analyses, the study may : 
• suspend enrollment to GT0918 treatment arm demonstrating lack of efficacy, and/or  
• initiate/expan d enrollment to the existing GT0918 treatment arm  
The modifications proposed are done so to ensure subject s are being exposed to treatment with 
an acceptable risk -benefit profile during the ongoing study . Additionally, the potential 
modifications will pro vide information to characterize the dose response profile more fully.  
Monitoring of unblinded safety data (including AEs, SAEs, and selected laboratory 
measurements) will occur throughout the study and will be conducted by IDMC  members.  
4.3 End of the st udy 
A subject is considered to have completed the study if he has completed all require d phases of the 
study including the last scheduled procedure shown in the SoA.  
The end of the study is defined as the date of last scheduled procedure shown in the SoA for the  
last enrolled subject or last ongoing subject in the study , whichever comes later.   
4.4 Early Study Termination  
The study can be terminated at any time for any reason by Kintor. Should this occur, the subject 
should be seen as soon as possible and the same assessments should be performed as described in 
Section 7 for a discontinued or withdrawn subjects. The investigator may be informed of 
additional procedures to be followed in order to ensure that adequate consideration is given to 
the protection of the subject’s interest. The investigator will be responsible for informing IRBs 
and/or ECs of the early termination of the trial.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
32 
 5 POPULATION  
5.1 Patient Population  
The target population of this study are those adult  subjects  with mild to moderate COVID -19 
illness  with first positive SARS -CoV -2 virus test within 3 days , to evaluate if anti -androgen 
therapy may effectively prevent progression to the severe form of COVID -19 illness by treating 
this population early in their disease course and prior to respiratory compromise and failure.  This 
study plans to have around 668 subjects in the US or may exp and to other countries/regions for 
GT0918 and the p lacebo groups, the randomization rate is 1:1.  
5.2 Inclusion Criteria  
Subjec ts are eligible to be included in the study only if all the following criteria apply:  
1. The subject or legally authorized representative give signed informed consent which includes 
compliance with the requirements and restrictions listed in the ICF and in th is protocol.  
2. Understand and agree to comply with planned study procedures . 
3. Male and non -pregnant female  subjects with age ≥18 years of age at the time of 
randomization . 
4. Are currently not hospitalized . 
5. Have one or more COVID -19-related symptoms within 5 days of symptoms onset ((FDA 
COVID -19-Related symptom guidance , See Appendix 2 , available at: 
https://www.fda.gov/media/142143/download ) 
6. Must have first positive SARS -CoV -2 viral infection determination (has laboratory -
confirmed SARS -CoV -2 infection as determined by PCR, or other commercial or  public 
health assay in any specimen) ≤3 days prior to start of the first dose . 
7. Women of child -bearing p otential, defined as all women physiologically capable of 
becoming pregnant, unless they are using highly effective contraception, as shown below, 
throughout the study and for 3 months after stopping GT0918 treatment. Highly effective 
contraception methods  include:  
• Total Abstinence (when this is in line with the preferred and usual lifestyle of the 
patient. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception, or   
• Use of one of the following combinations (a+b or a+c or b+c):   
a: Use of oral, injected or implanted hormonal methods of contraception or other 
forms of hormonal contraception that have comparable efficacy (failure rate < 
1%), for example hormone vaginal rin g or transdermal hormone contraception.   
b: Placement of an intrauterine device (IUD) or intrauterine system (IUS);  
c: Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository;  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
33 
 • Female sterilization (have had prior surgical bilateral oophorectomy with or without 
hysterectomy) or tubal ligation at least six weeks before taking study treatment. In 
case of oophorectomy alone, only when the rep roductive status of the woman has 
been confirmed by follow -up hormone level assessment;  
• Male sterilization (at least 6 months prior to screening). For female subject s on the 
study, the vasectomized male partner should be the sole partner for that subject ; 
In case of use of oral contraception women should have been stable for a minimum of 3 
months before taking study treatment. Women are considered post -menopausal and not of 
childbearing potential if they have had 12 months of natural (spontaneous) amenorrhe a with 
an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have 
had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 
six weeks ago. In the case of oophorectomy alone, only when t he reproductive status of the 
woman has been confirmed by follow up hormone level assessment, is she considered not of 
childbearing potential  
8. Regardless of their fertility status, male subjects must agree to either remain abstinent (if this 
is their prefer red and usual lifestyle) or use condoms as well as one additional highly 
effective method of contraception (less than 1% failure rate) or effective method of 
contraception with nonpregnant women of childbearing potential partners for the duration of 
the st udy and until 90 days after the last dose.  
9. Agree to the collection of nasopharyngeal swabs and venous blood . 
5.3 Exclusion Criteria  
Subjects are excluded from the study if any of the following criteria apply:  
1. Have SpO 2 ≤ 93% on room air at sea level or PaO 2/FiO 2 < 300, respiratory rate ≥30 per 
minute, heart  rate ≥125 per minute (FDA resource page, 
https://www.fda.gov/media/137926/download ) 
2. Estimated glomerular filtration rate (eGFR) < 30 ml/min  
3. Serum total bilirubin > 1.5 x ULN (upper limit of normal)  and AST and ALT >3 x ULN  
4. Subjects with significant cardiovascular disease  as following:  
i. heart failure NYHA class ≥3 
ii. left ventricular ej ection fraction <50%  
iii. those with a history of cardiac arrhythmias, including long QT syndrome.  
5. Has been admitted to a hospital prior to randomization, or is hospitalized (inpatient) at 
randomization, due to COVID -19 or requires treatment with supplemen tal oxygen.  
6. Have known allergies to any of the components used in the formulation of the interventions . 
7. Have hemodynamic instability requiring use of vasopressors within 24 hours of randomization . 
8. Suspected or proven serious, active bacterial, fungal, viral, or other infection ( except  
COVID -19) that in the opinion of the investigator could constitute a risk when taking 
intervention (i.e. known history  of human immunodeficiency virus [HIV]). 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
34 
 9. Have any co -morbidity requiring surgery within <7 days,  or that is considered life -threatening 
within 30 days. 
10. Have any serious concomitant systemic disease, condition, or disorder that, in the opinion of 
the investigator, should preclude participation in this study.  
11. Subjects  with myopathy  
12. Prior, current, or planned future use of any of the following treatments: COVID -19 
convalescent plasma, mAbs against SARS -CoV -2, IVIG (any indication) , where prior use is 
defined as the past 30 days or less than 5 half -lives of the investigational product (which is 
longer) from screening . 
13. Have participated, within the last 30 days before  dosing , in a clinical study involving an 
investigational intervention. If the previous investigational intervention has a long half -life, 
5 half-lives or 30 days, whichever is lon ger, should have passed.  
14. Are concurrently enrolled in any other type of medical research judged not to be scientifically 
or medically compatible with this study.  
15. Subject taking or had taken an anti -androgen of any type including androgen depravation 
therap y, 5-alpha reductase inhibitors, etc. within 3  month s before dosing .  
16. Are investigator site personnel directly affiliated with this study.  
 
6 TREATMENT  
6.1 Study Treatment  
For this study, study treatment in this study refers to GT0918  in the treatment arm and placebo in 
the placebo arm. GT0918  will be supplied by Kintor or its designee as 100 mg tablets as 
individual patient supply packaged in blister.  All dosages prescribed and dispensed to the patient 
and all dose changes during the study must be recorded on the Dosage Administration  Record 
eCRF.   
6.1.1 Dosing Regimen  
Eligible subjects will be randomized before  or on Day 1 to receive either  GT0918 or matched 
placebo.  GT0918/placebo will be given  200mg orally once daily on Days 1 -14 during the study 
period. Days 1 5-28 will be the post-treatment period without dosing with GT0918/placebo.  
The study drug will be administered as a flat -fixed dose and not by body weight or body surface 
area. The dose should be given the same time each day (+/ - 2 hours for medication scheduling)  
around 30 minutes after meal for consecutive 14 days. During scree ning visit  (D-1) or D1, after 
confirmation of subject’s eligibility, the drugs or placebo as well as Subject Diary with 
Questionnaire will be provided to subjects. The s ubject will document the dose date/time with 
the Diary and answer the Questionnaire dai ly.  
The study treatment period  is shown as below . 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
35 
  
Figure 5. Overview of study period  and group  assignment  
The investigator or responsible personnel will instruct the subject  to take the study drugs as 
per-protocol. Subject s will be instructed to return unused study drugs  (if applicable)  to the sites 
at discontinuation or completion of treatment. The site personnel will ensure that appropriate 
dose of each study drug is administered,  and that drug accountability is performed.  
 
6.1.1.1 General Dosing Guidelines  
The study treatments should be taken as follows:  
• Subject s should be instructed to take the study treatment of GT0918 /placebo two tablets 
together with a glass of water once a day at the same time each day.  
• In general, study treatment may be  taken after normal conventional meal ( ± 2 hours for 
medication scheduling) . 
• Subject s will be instructed to swallow the tablets whole and not to chew or crush them.  
• If vomiting occurs, during the course of treatment, no re -dosing of the drug is allowed before 
the next scheduled dose. The occurrence and frequency of any vomiting during the treatment 
period must be noted in the AEs section of the eCRF. Missing dose should be documented at 
Subject Diary.  
• Any doses that are mis sed should be skipped and should not be replaced or made up on a 
subsequent day.  
• Subject s try to  avoid consumption of grapefruit, grapefruit hybrids, pomelos, starfruit, 
Seville oranges or products containing their juice during the treatment period. These foods 
are known as CYP3A4 inhibitors and have a potential to increase exposure to GT0918 . 
Orange  juice is allowed.  
• Multivitamins are  permitted . 
6.1.2 Guidelines for Continuation of Treatment  
The treatment course continues as described above even if the subject becomes SARS -CoV -2 
test negative.  

  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
36 
 6.1.3 Ancillary Treatments  
This section is not applicabl e for this study.  
6.1.4 Rescue Medication  
This section is not applicable for this study.  
6.1.5 Treatment Duration  
The treatment period starts from Day 1 (first oral administration  of drug or placebo) to D 14, 14 
consecutive days . 
6.2 Dose Escalation  
This section is not applicable for this study.  No dose escalation or de -escalation is allowed 
through the whole study.  
6.3 Dose Modifications  
6.3.1 Dose Discontinuation  
Any subject who  develops ≥ Grade 3 treatment emergent adverse events that are possibly,  
probably or definitely related to the study drug as assessed by the investigator  will discontinue 
the treatment. There is no dose interruption or dose reduction in this study.  
The treatment cou rse should be continue d if the subject becomes SARS -Cov-2 test negative or 
experiences complete resolution of symptoms.  
 
For the subjects who are hospitalized during the study , the subject may continue the study 
treatment at the investigator’s discretion based on individual benefit/risk assessment . 
6.3.2 Follow -Up for Toxicities  
Subjects, whose treatment is permanently discontinue d due to an AE must be followed up at least 
twice a week  if applicable  (or more frequently if required by institutional practices, or if 
clinically indicated) for 4 weeks or until resolution or stabilization of the event , whichever comes 
first. Appropriate clinical experts should be consulted as deemed necessary.   
All AEs/SAEs w ill be followed until resolution, stabilization, the event  is otherwise explained, or 
the subject  is lost to follow -up (Section 7.1.6 ). Further  information on follow -up procedures is 
provided in Section 8.1 . 
6.3.3 Anticipated Risks and Safety Concerns of the Study Treatment  
Appropriate eligibility criteria and stopping rules are included in this protocol. Recommended 
guideline for supportive treatment for expected toxicities, including management of study  drug 
induced AEs are provided in Section 6.3.2 . More anticipated risks and safety concerns, r eference 
of preclinical toxicity and clinical data are in the IB.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
37 
 6.4 Concomitan t Medications  
In general, the use of any concomitant medication/therapy deemed necessary for the care of the 
subject  is permitted, except when specifically prohibited.   
The subject  must be told to notify the investigational site about any new medication he  takes 
after the start of study treatment. All medications, including herbal /natural  medications  
(excluding study treatment ), surgeries,  and procedures (including physical therapy) administered 
within 30 days prior to the first dose of administration of st udy treatment through 28 days after 
the last dose of  administration study treatment will be recorded in the concomitant medications 
or surgical and medical procedures eCRF, respectively.  
 6.4.1 Permitted Concomitant Therapy  
Prior Treatment for Indication  
Any prior therapy, such as antivirals, antibiotics, o r antimalarials used as treatment prior to  signing 
informed consent should be recorded.  
Therapy prior to enrollment with antivirals including lopinavir/ritonavir, remdesivir, or other  
therapeutic agents ( e.g., corticosteroids) are permitted.  
Concomitant Th erapy  During  the Study  
Subject s should be treated according to standard of care, even as it evolves, and medications  may 
be part of the treatment paradigm.  
Therefore, remdesivir may be initiated as standard of  care for subject s hospitalized with severe 
disease (if available through the FDA Emergency  Use Authorizations) outside of local standard 
of care per written policies or guidelines.  
If the local standard of care per written policies or guidelines (that is, not just an individual  
clinician dec ision) includes lopinavir/ritonavir, chloroquine, hydroxychloroquine or other  
investigational agents, then initiating these during the study is permitted, but may require  
additional safety monitoring by the site.  
Acetaminophen and corticosteroid use are pe rmitted during the study per investigator’s 
discretion.  
Other concomitant medication may be considered on a case -by-case basis by the investigator in  
consultation with the Sponsor  if required.  
Any medication, including not only physician prescribed medica tions, but also all over -the counter 
(OTC) medications, herbal medications , vitamin supplements, blood transfusion or other s that the  
subject  is receiving at the time of enrollment or during the study must be recorded  along with ： 
• Reason for use  including standard of care for COVID -19. 
• Dates of administration including start and end dates . 
• Dosage information including dose and frequency for concomitant therapy.  
 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
38 
 The Sponsor  should be contacted if there are any questions regarding concomitant or p rior 
therapy.  
6.4.2 Prohibited  Concomitant Therapy  
Strong CYP3A enzyme inhibitors and  inducers and P -gp transporter inhibitors and   inducers  are 
prohibited.  
Any medicine or treatment may influence evaluation of efficacy of study drug is prohibited, 
Spiron olactone,  anti-androgen drug or treatment including but not limited to 5α-Reductase 
Inhibitors, andro gen deprivation therapy, Enzalutamide, Bicalutamide,  Abiraterone. Or 
Cycloprogesterone, Androgen, Estrogen or AR antagonists . 
Convalescent COVID -19 plasma treatment is not allowed . The monoclonal  antibody therapy 
Bamlanivimab  alone , or Casirivimab and Imedevimab  in combination under the EUA for the 
treatment of mild  to moderate COVID -19 patients is prohibited in this study . 
6.4.3 Concomitant Therapy to Be Used with Caution  
Concomitant treatment of GT0918  with weak inhibitors or inducers of CYP3A4 is permitted. 
Caution is advised when GT0918  is co-administered with drugs that are moderate/strong 
inhibitors or inducers of CYP3A 4. Duration of concomitant treatment should be kept as short as 
possible, or completely avoided whenever possible. Subject s receiving such medications must be 
monitored closely for any potential toxicity or decrease d clinical benefit due to any individual 
concomitant medications.  
Concomitant treatment of GT0918  with medications which have narrow therapeutic 
index/sensitive substrates for CYP3A4/2D6 is allowed with caution. Detail ed lists of inhibitor, 
substrates and inducers of CYP3A or pertinent medicines are listed to Appendix 1.  
Any narrow therapeutic index/sensitive CYP 3A, or 2D6, or both substrate drug(s)  should be 
excluded from patient use if possible, then switch to a suitable alternative drug(s). If no suitable 
alternatives are available , it is recommend ed to reduce the dose of the narrow therapeutic 
index/sensitive CYP 3A, or 2D6, or the  substrate drug(s).  
Inducers or nutritional supplement of cytochrome P450 3A4 , such as St. John’s Wort Extract 
grapefruit , and i mmunosuppression medicine  are needed to be used with caution.  
6.5 Patient number ing, Treatment Assignment or Randomization  
6.5.1 Patient number ing 
Each subject will be assigned with unique number after signing off the inform consent form, 
which is the screening number, composite with site number 001 and subject number 001, 002…. 
After the screened subject is confirmed eligible to randomization, the screen number will service 
as the randomization number. Screen failure subject’s number will not be assigned to other 
subject s. Re -screen may not be allowed, but retest with screening window or on D1 is allowed.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
39 
 6.5.2 Treatment Assignment or Randomization  
All subject s will be centrally randomized to study intervention using an interactive web  response  
system (IWRS ). Before the study is initiated, the log -in information and directions for  the IWRS 
will be provided to each site . Subject s will be stratified by sex, race/ethnicity  and risk factors of 
COVID -19 (Section 4.1.1 ).  
All eligible subject s will be randomized initially following an equal allocation to treatment  arms. 
Given the staggered start of the treatment arms, periodic adjustments to the allocation  ratio, 
informed by planned interim analyses, may be made to achieve an equal allocation across  the 
treatment arms at the end of enrollment.  
6.5.3 Treatm ent Blinding  
This is a double -blinded study. Neither subject s, nor investigators, nor the Sponsor  study team 
will be aware of treatment assignments prior to the final data  base lock at the conclusion of the 
study.  
Unblinding procedures for this study  
• Emergency unblinding for AEs may be performed through the IWRS. All actions 
resulting in an unblinding event are recorded and reported by the IWRS . 
• In case of an emergency, the  investigator has the sole responsibility for determining if 
unblinding of a subject s’ intervention assignment is warranted . 
• Subject  safety must always be the first consideration in making such a determination. 
However, the investigator should make all att empts to contact the medical monitor in 
advance of unblinding . 
• If a subject ’s intervention assignment is unblinded, the Sponsor  must be notified 
immediately after breaking the blind even if consultation occurred in advance . 
• The date and reason that the bli nd was broken must be recorded in the source  
documentation and case report form . 
The investigator  has the right to determine whether the subject is still ongoing with the treatment 
even unblinded based on the best interest of the subject. Investigator is encouraged to discuss 
with medical monitor or Sponsor .  
6.6 Study Treatment Supply  
First supply of study supplies plus the study drug s will be shipped to sites within 2 weeks before 
site initiation visit.  Subsequent supplies will be provided upon sites request  or automatically 
initiated  via IWRS, which may be changed per local guidance a nd situation . The s ite needs to 
proactively inform Sponsor  and CRO the numbers of potential subjects. Fourteen  days dose of 
study drugs and placebo will be dispensed once by site staff during screening visit or D1 after 
eligibility is confirmed.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
40 
 6.6.1 Stu dy Treatment Preparation and Dispensation  
The investigator or designee must confirm appropriate temperature conditions  (if applicable)  
have been  maintained during transit for all study intervention received and any discrepancies are 
reported  and resolved before use of the study intervention.  
Only subject s enrolled in the study may receive study drugs  or matched placebo  and only 
authorized site  staff may supply and dispense them . 
All study drugs  must be stored in a secure, environmentally controlled, and monitored  (manual 
or automated) area in accordance with the labeled storage conditions with access limited  to the 
investigator and authorized site staff.  
The investigator, institution, or the hea d of the medical institution (where applicable) is  
responsible for study intervention accountability, reconciliation, and record maintenance (i.e.,  
receipt, reconciliation, and final disposition records).   
Further guidance and information for the final dis position of unused study interventions are  
provided in the pharmacy manual.  
6.6.2 Study Treatment  Packaging and Labeling  
GT0918 is an AR antagonist (MW 517.5 g/mol). The dosage  form for clinical research is a 100 
mg tablet weighing 320 mg per tablet. The 1 00 mg tablet is  circular in shape with 10 mm in 
diameter. The color is light yellowish. The drug product tablets  are packaged in PTP aluminum 
and PVC blister foils. These packaging materials are in  compliance with 21  Code of Federal 
Regulations (CFR ) 174-186 – Indirect Food Additive Regulations.  Table 1: Summary of Study 
Drugs  provides a summary of the finished study drug products.  
 
Table 1: Summary of Study Drugs  
Study Drug Name  GT0918  Matched Placebo  
Dosage Formulation  Tablet  Tablet  
Identity of Formulation  100mg  placebo  
Route of Administration  Oral Oral 
Dosing Instructions  Once Daily  Once Daily  
Packaging and Labeling  The 100 mg tablet is  
circular in shape with 10 mm in 
diameter, color is light 
yellowish. Packaged in PTP 
aluminum and PVC blister foils. 
Each blister will contain 7 
tablets and will be labeled as 
required per country 
requirement.  The matched placebo is  
circular in shape with 10 mm in 
diameter, color is light yellowish. 
Packaged in PTP aluminum and 
PVC blister foils. Each blister will 
contain 7 tablets and will be labeled 
as required per country requirement.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
41 
 Number and Time of Drugs  Treatment period: 2 tablets daily  Treatment period: 2 tablets daily  
6.6.3 Drug Supply and Storage  
The recommended storage conditions for GT0918 tablets are room temperature  with a shelf -life 
of 2 years. All drug supplies will be provided by the Sponsor  or CRO .  
Study treatments must be received by designated personnel at the study site, handled and stored  
safely and properly, and kept in a secured location to which only the investigator and de signated  
site personnel have access. Upon receipt, the study treatment should be stored according to the  
instructions specified on the drug labels and in the [Investigator’s Brochure].  
6.6.4 Study Treatment Compliance and Accountability  
The investigation site will maintain records of study drug delivered to  the study site; the 
inventory at the site; the distribution to and use by each subject; and the return  of study drug to 
the Sponsor  for storage and/or disposal  if applicable.  These records  should include dates,  
quantities, batch/blister card/pouch/serial numbers, expiration dates, in -clinic temperature log(s),  
and unique code numbers assigned to the study drug s and study subjects.  
At each visit after initiation of treatment, site staff will  record compliance of subjects with their  
assigned regimen. Subjects will be instructed to bring their subject diaries  at each study visit. 
Subjects are to  be reminded of the importance of compliance with their assigned regimen, with 
an emphasis on  taking their study drug on schedule and maintaining the prescribed interval 
between doses.  
Investigators will maintain records that document adequately that the subjects were provided  
with the correct study drug s and will reconcile the products received from the drug dispensing  
center.  
Medication containers must be returned at each visit, as compliance will be assessed by tablet  
counts. Non -compliance is defined as taking less than 80% or more than 120% of study drug  
during any outpatient evaluation period (visit  to visit). Discontinuation for non -compliance is at  
the investigator’s discretion and is to be noted on the eCRF.  
6.6.5 Disposal and Destruction  
Study drug s will not be returned to the Sponsor  or destroyed at the clinical site until  
accountability has been fully determined.  
After the study treatment period has ended or as appropriate over the course of the study after  
study product accountability has been performed; used or unused tablets should be returned to 
the Sponsor  or destroyed on -site following applicable site procedures or by the site’s selected 
destruction vendor. Following the site’s procedure for the destruc tion of hazardous material or 
study product destruction  policy/standard operating procedure (SOP) when destroying used and 
unused items. A certificate of destruction should be provided to the Sponsor  and retained in the 
Pharmacy Binder once completed.  
 
 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
42 
 7 VISIT SCHEDULE AND ASSESSMENTS  
7.1 Study Flow and Visit Schedule  
This study contains up to 1-day screening visit (D -1), 14 days treatment (D1 -D14), additional  28 
days safety follow -up period (D1 5-D42). See the SoA  
7.1.1 Screening  
After signing the study informed consent, the screening assessments will be done within 1 day 
prior to randomization ( See SoA). Re -screening is not allowed in this study.  
7.1.1.1 Eligibility Screening  
In order to determine and conform the eligibility of the subject, once all screening procedures are 
completed, an eligibility checklist must be completed via IRT by the investigator or  designee 
prior to randomization. Please refer and comply with detailed guidelines in the IRT manual.  
7.1.1.2 Information to Be Collected on Screening Failures  
A subject  who sign s the informed consent but fail s to start on -treatment for any reason will be 
considered a screen failure. The reason for not starting on-treatment will be entered on the 
screening failure page or screening disposition page . The demographic information, informed 
consent, and inclusion/ exclusion pages must also be completed for screen failure subject s. No 
other data will be entered into the clinical database for subject s who are screen failures unless  the 
subject  experienced a serious AE during the screening phase.  
7.1.1.3 Subject  Demographics and Other Baseline Characteristics  
The data that will be collected at screening includes:  
 Demography (date of birth and initials  (where permitted), sex, race, ethnicity) , BMI . 
 Diagnosis (date and method of c onfirm ation  the positive SARS -CoV -2 test result) . 
 Days from onset  of COVID -19 symptoms prior to first dosing . 
 Medical History (including medication allergy history) /current medical conditions  (e.g., all 
current medical conditions which are present at the time of signing informed consent). High -
risk status for severe COVID -19 illness ( such as hypertension , diabetes , coronary artery 
disease, obesity , chronic kidney disease, smoker, androgenic alopecia etc.). Ongoing 
medical conditions, symptoms and disease which are recorded on the medical history eCRF 
should include the toxicity grade . 
 All medications and significant non -drug therapies taken within 30 days before the first dose 
is administered, they must be recorded on the Prior and Concomitant medication or Surgical 
and medical procedures eCRF page and updated on a continual basis if th ere are any new 
changes to the medications . 
 Patient  reported symptom  questionnaires . 
 Counsel subjects to use adequate birth control methods required during the study  to avoid  
pregnancy.  
 Obtain vital sign s (including as below)  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
43 
 o Height and weight are  only needed at screening  
o Body temperature . 
o Systolic blood pressure (BP), diastolic BP . 
o Pulse rate . 
o Respiration rate . 
o Saturation of peripheral oxygen if applicable . 
o Supplemental oxygen flow rate, FiO 2 if known, and method of delivery, if applicable 
or clin ical indicated.  
o Additional vital signs may be measured during the study if warranted, as determined 
by the investigator.  
 Review recent radiographic imaging ( X-ray or CT -scan) if applicable  
 A complete physical examination will be performed at the screening  visit.  
o This examination excludes pelvic, rectal, and breast examinations unless clinically 
indicated.  
o A symptom  directed physical examination will be performed at other visits, as 
specified in the SoA and as clinically indicated.  
o Investigators should pa y special attention to clinical signs related to COVID -19, to 
ongoing medical conditions and to previous serious illnesses.  
 Obtain blood for screening laboratory evaluations . 
 Serum pregnancy test ( regardless of childbearing potential).  
The first-time confirmed SARS -CoV -2 positive at local laboratory and/or Point of Care testing.  
Sample must be collected within 3 days prior to start of  dosing . Clinical  screening laboratory 
evaluations will be performed locally by the site. The overall eligibility of the subject to 
participate in the study will be assessed once all screening  values are available. The screening 
process can be suspended prior to complete a ssessment at  any time if exclusions are identified by 
the study team. Study subjects who qualify will be immediately randomized. Tests or 
assessments can be redone once per investigator’s discretion within the time window at 
screening visit. If a subject c annot meet inclusion and exclusion criteria during screening period, 
this subject is considered as screen failure, re -screening is not allowed.  
7.1.2 Treatment Period  
All subjects who are randomized to the study are considered as entering the treatment pe riod. 
The subjects will be treated 14 consecutive days or less due to AE, lost to follow -up or consent 
withdrawal . During the treatment period, subjects will self -administrated GT0918 or matched 
placebo orally  around  30 minutes after a meal,  the dose should be given the same time each day 
(+/- 2 hours for medication scheduling). Subjects also need to record the time/date of dose with 
provided Subj ect Diary daily as well as completion of the questionnaire which allows subjects to 
self-evaluate their COVID -19 symptoms. Any dose that is delayed may be given later that 
calendar day. Any dose that is missed (not given that calendar day) is not made up, which should 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
44 
 be documented as dose missing on Subject Diary with a reason.  The treatment course continues 
as described above even if the subject becomes SARS -COV-2 test negative . 
On Days 3, 7, 14 and 28, nasopharyngeal swab s will be collected for viral loa d tests, meantime 
vital sign or other assessments will be performed and PK samples collection will be done per 
Schedule of Activities (SoA) . On Day 14, safety laboratory tests are needed to evaluate clinical 
outcome and ensure safety. The above visits are preferred  subjects  in person to sites. However, 
infection control or other restrictions may limit the ability of the subject to return to sites. In this 
case, the visits may be conducted as outpatient clinic or home visits. The planned visit schedules 
and visit types/location should be discussed and confirmed during screening visit  with every 
subject,  any future  changes will be coordinated according in advance.  
Hospitalization should be closely monitored and documented with subject’s source and eCRF  as 
described in Section 7.2.1.1 . 
Meantime, the subjects’ clinical status as detailed in Secti on 7.2.1.2  will be recorded in the  
eCRF .  
7.1.3 End of Treatment  
  
7.1.3.1 Study treatment discontinuation  
 
Subject s may voluntarily discontinue from  study treatment for any reason at any time. If a 
subject decides to discontinue from study treatment, the investigator must make every effort (e.g. 
telephone, e -mail, letter) to determine the primary reason for this decision and record this 
information in  the subject’s chart and on the appropriate CRF pages. They may be considered 
withdrawn if they state an intention to withdraw , fail to return for visits, or become lost to 
follow -up for any other reason.  
The investigator should discontinue study treatmen t for a given subject if, on balance, he/she 
believes that continuation would be detrimental to the subject’s well -being.  
If oral administration of the study drugs is definitively discontinued, the subject will remain in 
the study for follow -up and any fur ther evaluations that need to be completed as described in the 
SoA.  
Subjects who completely discontinue study treatment should be scheduled for an End of 
Treatment visit within 2 days following the date study treatment is permanently discontinued, at 
which  time all of the assessment listed for the EOT visit will be performed. For details of 
assessment, refer to SoA. If the decision to discontinue occurs at a regularly scheduled visit, that 
visit may become the EOT visit rather than having the subject return  for an additional visit.  
An End of treatment eCRF page should be completed, giving the date and reason for stopping 
the study treatment. If a withdrawal occurs, of if the subject fails to return for visits, the 
investigator must determine the primary reas on for a subject’s premature discontinuation and 
record the information on the EOT eCRF page. The EOT visit is considered as end of study.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
45 
 At a minimum, all subjects who discontinue study treatment, including those who refuse to 
return for a final visit, w ill be contacted for a safety evaluation during the 28 days following the 
last dose of study treatment. At this time the occurrence of any component of the primary 
efficacy endpoint will be assessed as well.    
If a subject discontinues study treatment, but  continues study assessments, the subject remains on 
study until he /she completes protocol criteria for ending study assessments. At that time, the 
reason for study completion should be recorded on the end of study eCRF page.  
The investigator must contact the IRT to register the subject’s discontinuation.  
End of treatment/Premature withdrawal visit is not considered as the end of study.  
A subject may be withdraw n from the study  treatment earlier  due to following reasons : 
o AE 
o Lost to follow -up 
o Physician’s decision  
o Protocol deviation  
o Death 
o Subject/guardian decision  
o Study terminated by the Sponsor  
o Pregnancy  
o Others  
If the Sponsor  or investigator identify a subject who did not meet enrollment criteria and was  
inadvertently enrolled, then the subject  should be discontinued from study intervention unless  
there are extenuating circumstances that make it medically necessary for the subject to continue 
study intervention.  
If the investigator and the Sponsor  agree it is medically appropriate to continue, the investigator 
must obtain documented approval from the Sponsor  to allow the inadvertently enrolled subject to 
continue in the study with or without treatment with study drugs.  
7.1.4 Withdrawal of Consent  
Early withdrawal is expected to be uncommon.  
Subjects may voluntarily withdraw consent to participate in the study for any reason at any time. 
Withdrawal of consent occurs only when a subject:  
 Does not want to participate in the study anymore, and  
 Does not allow further collection of personal data.  
In this situation, the investigator should make a reasonable effort (e.g., telephone, email, letter) to 
understand the primary reason for the subject’s decision to withdraw his consent and record this 
information.  Study treatment must be discontinued, and no further assessment conducted. Further 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
46 
 attempts to contact the subjects are not allowed unless safety findings require further 
communication or follow -up. 
All efforts should be made to complete the assessments p rior to study withdrawal. A final 
evaluation should be made at the time of the subject’s study withdrawal.  
At the time of early withdrawal from the study, if possible, an early withdrawal visit should be 
conducted, which can be referred to in the SoA and the subject will continue to follow -up. If the 
subject withdraws consent for disclosure of future information, the Sponsor may retain and 
continue to use any data collected before such a withdrawal of consent. If a subject withdraws 
from the study, he may request destruction of any samples taken and not tested, and the 
investigator must document this in the site study records and inform Sponsor accordingly.  
7.1.5 Follow -Up for Safety Evaluations  
After the end of 14 days treatment period, subjects will enter a 14-day post -treatment (Day 15 -
Day 28 or 14 days after last dose) and another 14 -day safety follow -up periods  (Day 29 -Day 42 
or 14 days after post -treatment) during which information on the subject  will be collected  until 
Day 42 (± 2). Information will be collected by clinic, sites or home visit or other means as 
appropriate  on D28 (± 2).  Subject Questionnaire collected daily until Day 28. Day 42 (± 2) is a 
phone call.  All subjects are expected to complete  follow -up visit s except those lost to follow -up 
or consent withdraw al.  
Site personnel, or an independent third party, will attempt to collect the vital status of the  subject 
within legal and ethical boundaries for all subjects that received study intervention. Public 
sources may be searched for vital status information. If vital status is determined to be deceased, 
this will be documented, and the subject will not be considered lost to follow -up. Sponsor 
personnel will not be involved in any attemp ts to collect vital status information.  
The end of treatment eCRF page will be completed once a subject  has discontinued study 
treatment, then the subject will complete post -treatment and safety follow -up periods . 
On Day 28, nasopharyngeal swab s will be co llected for viral load tests, meantime vital sign or 
other assessments will be performed per SoA.  On Day 28, the safety laboratory tests are needed 
to evaluate clinical outcome and ensure the safety. The Day 28  visit is preferred for subjects to 
attend in person to sites. However, infection control or other restrictions may limit the ability of 
the subject to r eturn to sites. In this case, the visit may be conducted as outpatient clinic or home 
visits. The planned visit schedules and visit types/location should be discussed and confirmed 
during screening visit with every subject, any future changes will be coord inated according in 
advance.  
Subjects whose treatment is discontinued due to an AE, must be followed until resolution or 
stabilization of the event, whichever comes first. This could include all study assessments 
appropriate to monitor the event.  Data col lected should be added to AE CRF and the 
Concomitant Medications CRF.  
7.1.6 Lost to Follow -Up 
For subject s whose status is unclear because they fail to appear for study visits without stating an 
intention to withdraw consent, the investigator should show “ due diligence” by contacting the 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
47 
 subject , family or family physician as agreed in the informed consent and by documenting in the 
source documents steps taken to contact the subject , e.g., dates  of telephone calls, registered 
letters, etc. A subject  should not be considered lost to follow -up until due diligence has been 
completed. Subject s lost to follow -up should be recorded as such on the appropriate disposition 
CRF.  
7.1.7 End of Safety  Follow -Up 
The end of post -treatment phase disposition eCRF page will be completed once a subject has 
discontinued study treatment, completed safety follow -up. 
End of post -treatment follow -up may occur one of the following reasons:  
• AE 
• Lost to follow -up 
• Physician’s decision  
• Progressive disease  
• Subject/guardian decision  
• Death 
• Protocol deviation  
• Pregnancy  
• Study terminated by the Sponsor  
• Others  
7.2 Assessment  
Planned time points for all safety assessments are provided in the SoA.  
7.2.1 Efficacy Assessments  
  
Non-Hospitalization events  (7.2.1.1 ), NIAID ordinal scale (7.2.1.2 ) , symptom improv ement and 
resolution( 7.2.1.3 ) will be used to characterize the effect of GT0918  compared t o placebo on 
clinical status from baseline to Days 14 and 28.  
7.2.1.1 Composite  Events  for non-Hospitalization  
The following  events  by Day 28 will be collected  and recorded in the eCRF:  
• Hospitalization (defined as ≥24 hours)  
• Supplemental oxygen for ≥24 hours  
• Death  
The date of hospitalization events as above will be recorded in the eCRF . Additionally, the date 
for following events will also be recorded in the eCRF.  
• Emergency room visit  
• ICU admittance  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
48 
 • Discharge   
• Extended care facility admittance (refers to long term care for chronic diseases or 
prolonged rehabilitation, which is not defined as hospitalization)  
7.2.1. 2 NIAID Ordinal  Scale 
The National Institute of Allergy and Infectious Diseases (NIAID) Ordinal Sca le will be assessed 
by the site daily beginning on Day 1 thr ough Day 28 using AE and Questionnaire data. NIAID 
Ordinal Scale outcomes will be analyzed on Day 7, Day 14 and Day 28.  
NIAID Score Description  
The NIAID scoring scale will be assessed  daily and defined as the lowest score achieved for that 
day. 
The scoring is based on the clinical status of the patient as described below.   
1. Death  
2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation 
(ECMO)  
3. Hospitalized, on non -invasive ventilation or high flow oxygen devices  
4. Hospitalized, requiring supplemental oxygen  
5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care 
(COVID -19-related or other medical conditions  preventing hospital discharge ) 
6. Hosp italized, not requiring supplemental oxygen - no longer requires ongoing medical care  
7. Not hospitalized, limitation on activities and/or requiring home oxygen  
8. Not hospitalized, no limitations on activities  
The subjects’ following conditions  will be recorded  in the CRF and include limitation on 
activities due to COVID -19: 
• Ongoing hospital medical care  
• Supplemental oxygen  
• Non-invasive ventilation or a high flow oxygen device  
• Mechanical ventilation  
• ECMO  
Subjects will also complete 3 questions about NAIDS as following in the patient questionnaire:  
• Home oxygen  
• Limited activities  
• Hospitalization  
 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
49 
 7.2.1.3 Symptom improvement and resolution  
Subject s will rate their overall clinical status and severity of symptoms associated with  
COVID -19 by a daily questionnaire. This questionnaire is for outpatients only.  
Subject s will complete 3 questions about their overall clinical status daily, including  
• Severity of symptoms  
• General physical health, and  
• Change in over all health  including activity limitation, home oxygen, hospitalization, etc.  
The questionnaire contains these symptoms  
• Cough  
• Shortness of breath  
• Feeling feverish  
• Fatigue  
• Body aches and pain  
• Sore throat  
• Chills 
• Headache  
• Nausea  
• Vomiting  
• Diarrhea  
• Changes in taste and smell.  
Each symptom will be scored daily by the subject  as experienced during the past 24 hours.  
Detailed list of symptoms and r ating score guideline is document per Appendix 5.  
7.2.2 Safety and Tolerability Assessments  
Safety assessments are specified below with the assessment schedule detailing when each 
assessment is to be performed.  
For safety evaluations, baseline is defined as assessments done on D ay 1 prior to the first dose of 
study treatment . 
The investigator will repor t any vital signs considered clinically significant in the eCRF. For 
details on AE collection and repo rting refer to AE Section  8.1. 
7.2.2.1 Physical Examinations  
A complete physical examination will be performed at the screening visit. This examination  
excludes pelvic, rectal, and breast examinations unless clinically indicated.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
50 
 A symptom  directed physical examination will be performed at other visits, as specified in the  
SoA and as clinically indicated.  
Investigators should pay special attention to clinical signs related to COVID -19, to ongoing 
medical  conditions and to previous serious illnesses.  
7.2.2.2 Vital Signs  
Vital signs will be measured as specified in the So A and as clinically indicated. Vital sign 
measurements to be measured in the sitting position after 5 mins rest  if applicable . Vital signs 
include : 
o Height and weight are  only needed at screening   
o Body temperature  
o Systolic BP, diastolic BP  
o Pulse rate  
o Respiration rate  
o Saturation of peripheral oxygen  
o Supplemental oxygen flow rate, FiO 2 if known, and method of delivery, if applicable 
or clinical indicated.  
Additional vital signs may be measured during the study if warranted, 12 -ECG assessment as  
determined by the investigator.  
7.2.2.3 Clinical Laboratory Tests  
Local clinical laboratory parameters will be used for the analysis of scheduled hematology, 
chemist ry and other blood specimens collected as part of safety monitoring (as detailed in SoA) 
and the results will be collected in the eCRF , except for specific parameters which will be 
performed centrally by a Kintor designated laboratory ( as detailed in Appen dix 4).  
Unscheduled assessments of these parameters can be performed more often as clinically 
indicated. It is preferable to use the same laboratory for all the assessments performed, especially 
for hematology.  
Laboratory values obtained  during the scree ning phase will be used to assess subject’s eligibility.  
The local lab oratory  must provide Kintor with a copy of the certification and a tabulation of 
normal ranges and units for all local laboratories used in the study . 
Clinically significant abnormalitie s must be recorded as either medical history/current medical 
conditions or AEs as appropriate.  
There are no specific notable range criteria for this study; however, the local and central 
laboratory will flag laboratory  values falling outside of the normal range, on the local and central 
laboratory report  (as applicable) ( which the investigator should sign off) as per local practice, 
and the investigator will report any values considered clinically significant in the eCRF.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
51 
 See Appendix 4 for the list of clinical laboratory tests to be performed and the SoA  for the timing 
and frequency.  
All protocol -required laboratory assessments, as defined in  Appendix 4 must be conducted in 
accordance wit h the laboratory manual and the SoA. 
Clinically significant abnormal laboratory findings are those which are not associated with the  
underlying disease, unless judged by the  investigator to be more severe than expected for the  
subject's condition.  
All laboratory tests with values considered clinically significantly abnormal during participation  
in the study or within 28 days after the dose of study intervention should be repeated until the 
values return to normal or base line or are no longer considered clinically significant by the  
investigator or Sponsor . If such values do not return to normal/baseline within a period judged 
reasonable by the  investigator, the etiology should be identified, and the Sponsor  notified.  
The investigator must review the laboratory report, document this review in timely manner, and 
record any clinically relevant changes occurring during the study in the AE section of  the CRF.  
The laboratory reports must be filed with the source documents.  
If laboratory values from non -protocol specified laboratory assessments performed at the  
institution’s local laboratory requires a change in subject management or are considered  
clinically significant by the investigator (e.g., SAE or AE or dose modification), report in the AE  
section of the CRF and this test is recorded as unscheduled visit in eCRF.  
7.2.2.4 Respiratory Support  
Once enrolled in the study, subjects may be managed with  high flow nasal cannula, non -invasive 
positive pressure ventilation or any other form respiratory support as needed per investigator 
discretion.  
7.2.2.5 Pregnancy and assessment of fertility  
All women  of childbearing potential must complete a serum pregna ncy test at screening visit, 
urinary pregnancy test at subsequent visits as per the schedule of assessment. Local laboratories 
will be used for the analysis of serum and urinary pregnancy tests.  
Women who are determined not to be of childbearing potential before the study will only be 
tested at screening.  
For postmenopausal women to be considered “of non -childbearing potential”, subjects should 
meet the criteria as outlined as following:  
Women are considered post -menopausal and not of  childbearing potential if they have had 12 
months of natural(spontaneous) amenorrhea with appropriate clinical profile (e.g., age 
appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with 
or without hysterectomy), total  hysterectomy or tubal ligation at least six weeks ago. In the case 
of oophorectomy alone, only when reproductive status of the woman has been confirmed by 
follow up hormone level assessment is she considered not of child bearing potential.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
52 
 Please refer to  Section 8.6 for information on reporting any pregnancies that occur while the 
subject is on study.  
If pregnancy test is performed in between study visits by the subject and the result is positive, the 
subject must immediately notify the investigator.  
7.2.3 Pharmacokinetics  
The exposure -response relationship of GT0918  in the treatment of SARS -CoV -2 has not been 
established. Population PK analyses can be used to further inform dose selection in other 
populations and support concentration -response investigations with efficacy and safety outcomes. 
To accomplish this, sparse PK sampling techniques can be employed. Samples will be collected at 
pre-dose and 2h post first dose, and at pre -dose on Day  3, 7 and 14  from at least  100 subjects  who 
receive  intervention and have evaluable PK.  
The PK data may be analyzed using validated LC -MS/MS methods with a LLOQ of 
approximately  5.00 ng/mL for GT0918 .  
7.2.4 Biomarkers  
Blood samples will be collected from all subject s for exploratory bio marker research at the time 
specified in the SoA  where local regulations allow.  
The following will be monitored:  
• C-reactive protein (CRP)  
• Testosterone  
• Ferritin  
• D-dimer  
• Procalcitonin  
• Troponin  
Samples will be stored and analysis may be performed on biomarkers thought to play a role in  
immune system related responses to viral infection including, but not limited to, immune  
pathways, cellular composition, serum analytes, or epigenetic biomarkers, to evaluate their  
association with observed clinical res ponses to GT0918  and the disease state.  
Samples may be used for research to develop methods, assays, prognostics and/or companion  
diagnostics related to the intervention target (S protein), the COVID -19 disease state, pathways  
associated with disease, and/ or the mechanism of action of the study intervention.  
7.2.5 Polymerase Chain Reaction (PCR)  
The second endpoint is the change from baseline to Day 3, 7, 14, 28 in SARS -CoV -2 viral load 
based on nasopharyngeal swab samples for reverse transcription -polymera se chain reaction (RT -
PCR) testing for SARS -CoV -2 (if it is not able to get the samples at each time point, reason 
should be documented with subject source or eCRF, for example,  due to lack of testing supplies, 
limited testing capacity, subject is able to go clinic or home visit is not able to schedule, etc.).   
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
53 
 Quantitative  RT-qPCR , which should be done in the central laboratory,  is to determine the viral 
load change from different time points. Samples may additionally be used for exploratory viral 
RNA sequ encing  or viral culture . Additional details regarding sample collection and analysis  can 
be found in the laboratory manual.  
7.2.6 Patient Reported Outcomes  
Subjects will be provided Subject’s Diary which will contain the study drug administration 
information (date/time, with or without meal), and the Symptoms and Overall Clinical Status 
Subject Questionnaire for subjects to self -evaluate their health status from their own perspective.  
The questionnaire is required to be completed dai ly, should at the same time each day (+/ - 2 
hours for medication scheduling), from screening  to end of follow -up at Day 28. Symptoms of 
COVID -19 are listed per FDA guidance ( https://www.fda.gov/medi a/142143/download ) and the 
questionnaire was modified based on this FDA guidance as well , referred to Appendix 5.  
The Sponsor  and investigators will make efforts to minimize the amount of missing data, include 
providing reminders (e.g., phone calls, text messages, email) to study  subjects to complete 
Patient Reported Outcomes (PRO) instruments, monitoring compliance with PRO instrument 
completion throughout the assessment period, following up with study  subjects who are not 
successfully completing PRO instruments (and, where permi ssible, close contacts if the study  
subject is not responding), and recording verbal responses for those who are unable to self -record 
because of illness or other circumstances. Sponsor and investigators/ sites will try to obtain 
contact information for cl ose contacts of study  subjects for use in case of nonresponse.  This such 
close contacts include family member (s) or other close contact when subjects do not respond to 
follow -up, this process is described in the informed consent document, will be (is) app roved by 
the institutional review board and agreed with subjects. The reasons for missing data should be 
documented with subject’s CRF.  
7.2.7 Virology  
Characterize the effect of GT0918 compared to placebo on SARS -CoV -2 viral load clearance : 
• Change from bas eline to Days 3, 7, 14 and 28 in SARS -CoV -2 viral load .  
• Proportion of subjects that achieve SARS -CoV -2 clearance (Days 3, 7, 14 and 28)  
• Time to SARS -CoV -2 clearance.  
• SARS -CoV -2 viral load area under the concentration -time curve (AUC) assessed to 
Days 3, 7, 14 and 28 . 
7.2.8 Development of resistance  
Characterize emergence of virus resistance to GT0918  
• Virus load assessment on Day -1/1(baseline prior to first dose) , 3, 7, 14, 28 .  
• Exploratory endpoints  will include:  
o Screening for novel mutants in patients who do not respond to GT0918 : 
▪ Genotype of SARS -CoV -2 viral isolates . 
For resistance analyses, include subjects who:  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
54 
 • Are not able to show two consecutive negative test results via RT -PCR testing by Day 
28,  
and/or  
• Show a positive real -time RT -PCR test result after two consecutive negative RT -PCR 
test results,  
and/or  
• A confirmed rise in SARS -CoV -2 RNA of ≥1 log10 after a chieving nadir on treatment.  
 
Characterize emergence of host resistance to GT0918  
• Testosterone levels on Day -1, 3, 7, 14, 28 .   
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
55 
 8. SAFETY MONITORING AND REPORTING  
8.1 Adverse Events  
8.1.1 Definitions and Reporting  
An AE is defined as the appearance of (or worsening of any pre -existing) undesirable sign(s), 
symptom(s), or medical condition(s) that occur after subject’s signed informed consent has been 
obtained . 
Adverse events that begin or worsen after informed consent should be recorded in  the AEs CRF. 
Conditions that were already present at the time of informed consent should be recorded in the 
Medical History CRF. Adverse event monitoring should be continued for 28 days following the 
last dose of study treatment. Adverse events (including  lab abnormalities that constitute AEs) 
should be described using a diagnosis whenever possible, rather than individual underlying signs 
and symptoms. When a clear diagnosis cannot be identified, each sign or symptom should be 
reported as a separate AE. 
Subjects will be instructed to report AEs during the study and staff will query subjects regarding 
AEs throughout the study. The investigator (and/or designee) must document all AEs reported by 
the subject from the time subjects give consent through completi on of the EOS visit. Any subject 
who is withdrawn from the study due to an AE shall be followed until the event has resolved or 
stabilized or 28 days after last dose and the investigator will document available follow -up 
information on the subject’s source documentation and CRF.  
Adverse events reported after consent but before the first dose of study treatment are still to be 
documented by the investigator but will be considered non -treatment -emergent AEs. Adverse 
events will be considered t reatment emergent if the onset date is after the first dose of study drug . 
All AEs and SAEs will be assessed for severity using the  Division of AIDS (DAIDS) Table for 
Grading the Severity of Adult and Pediatric Adverse Events, version 2.1 (July 2017).  
For AEs not included in the Table, the following guidelines will be used to describe severity. In  
addition, all deaths related to an AE  are to be classified as grade 5 according to the DAIDS Table.  
Mild: Mild symptoms causing no or minimal interference with usual social and functional 
activities, with intervention not indicated.  
Moderate: Moderate symptoms causing greater than minimal int erference with usual social and 
functional activities, with intervention indicated.  
Severe: Severe symptoms causing inability to perform usual social and functional activities, with 
intervention or hospitalization indicated.  
Potentially life -threatening: Potentially life -threatening symptoms causing inability to perform 
basic self -care functions with intervention indicated to prevent permanent impairment, persistent 
disability, or death . 
An event is defined as ‘serious’ when it meets at least 1 of the prede fined outcomes as described 
in the definition of an SAE, NOT when it is rated as severe.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
56 
 “Lack of efficacy” or “failure of expected pharmacological action” per se will not be reported as 
an AE or SAE. Such instances will be captured in the efficacy assessm ents. However, the signs, 
symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE 
if they fulfill the definition of an AE or SAE.  
8.1.2 Events NOT Meeting  the AE Definition:  
• The following study -specific clinical eve nts related to COVID -19 are exempt from AE 
reporting unless the investigator deems the event to be related to the administration of 
study drug:  
o Hypoxemia due to COVID -19 requiring supplemental oxygen;  
o Hypoxemia due to COVID -19 requiring non -invasive ventil ation or high flow 
oxygen devices;  
o Respiratory failure due to COVID -19 requiring invasive mechanical ventilation 
or ECMO . 
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the subject ’s condition.   
• The disease/disorder being studied or expected  progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the subject’s 
condition.  
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads 
to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start o f the study that do not worsen.  
Classification of AEs by Relationship to Study Drug  
UNRELATED: This category applies to those AEs that are clearly and incontrovertibly due 
to extraneous causes (disease, environment, etc.).  
UNLIKELY:  This category applies to those AEs that are judged to be unrelated to the test 
drug, but for which no extraneous cause may be found.  An AE ma y be considered unlikely to 
be related to study drug if or when it meets 2 of the following criteria:  (1) it does not follow a 
reasonable temporal sequence from administration of the test drug; (2) it could readily have 
been produced by the subject’s clini cal state, environmental or toxic factors, or other modes of 
therapy administered to the subject; (3) it does not follow a known pattern of response to the 
test drug; or (4) it does not reappear or worsen when the drug is re -administered.  
POSSIBLY: This c ategory applies to those AEs for which a connection with the test drug 
administration appears unlikely but cannot be ruled out with certainty.  An AE may be 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
57 
 considered possibly related if or when it meets 2 of the following criteria: (1) it follows a 
reason able temporal sequence from administration of the drug; (2) it could not readily have 
been produced by the subject’s clinical state, environmental or toxic factors, or other modes of 
therapy administered to the subject; or (3) it follows a known pattern of  response to the test 
drug.  
PROBABLY: This category applies to those AEs that the investigator feels with a high degree 
of certainty are related to the test drug.  An AE may be considered probably related if or when 
it meets 3 of the following criteria: (1 ) it follows a reasonable temporal sequence from 
administration of the drug; (2) it could not be reasonably explained by the known 
characteristics of the subject’s clinical state, environmental or toxic factors, or other modes of 
therapy administered to th e subject; (3) it disappears or decreases on cessation or reduction in 
dose (note that there are exceptions when an AE does not disappear upon discontinuation of 
the drug, yet drug -relatedness clearly exists; for example, as in bone marrow depression, fixe d 
drug eruptions, or tardive dyskinesia); or (4) it follows a known pattern of response to the test 
drug.  
DEFINITELY: This category applies to those AEs that the investigator feels are 
incontrovertibly related to test drug.  An AE may be assigned an attribution of definitely related 
if or when it meets all of the following criteria: (1) it follows a reasonable temporal sequence 
from administration of the drug; (2) it could not be reasonably explained by the known 
characteristics of the subject’s clini cal state, environmental or toxic factors, or other modes of 
therapy administered to the subject; (3) it disappears or decreases on cessation or reduction in 
dose and recurs with re -exposure to drug (if rechallenge occurs); and (4) it follows a known 
patte rn of response to the test drug.  
All AEs (regardless of seriousness or relationship to study drug) including those from the time of 
consent to the EOS visit are to be recorded in the subject’s source documents and on the 
corresponding page(s) in the CRF. The investigator should specify the date of onset, intensity, 
action taken with respect to study drug, corrective treatment/therapy given, outcome and his/her 
opinion as to whether there is a reasonable possibility that the AE was caused by the study drug . 
All medications administered to treat an AE must be recorded in the subject’s source 
documentation and reported in the CRF . 
8.1.3 Laboratory Test Abnormalities  
Laboratory abnormalities that constitute an AE in their own right (are considered  clinically 
significant, induce clinical signs or symptoms, require concomitant therapy,  or require changes in 
study treatment), should be recorded on the A Es CRF.  
Whenever possible, a diagnosis, rather than a symptom should be provided (e.g. anemia  instead of 
low hemog lobin). Laboratory abnormalities that meet the criteria for AEs should be followed until 
they have returned to normal or an adequate explanation of  the abnormality is found. When an 
abnormal laboratory or test result corresponds to a  sign/symptom of an alr eady reported AE, it is 
not necessary to separately record the  lab/test result as an additional event.  
Laboratory abnormalities, that do not meet the definition of an AE, should not be  reported as AEs. 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
58 
 8.2 Adverse Events of Special Interest (AESI)  
The Adverse events of special interest  (AESI) search table will be used to map reported AEs to 
the notable AE groupings. AESI could be updated during the course of study based on 
accumulating safety data. Therefore the clinical study report includes the AE gro upings  (such as 
gastrointestinal  disorders , cardiovascular  disorders , increased liver transaminase , and 
neurological disorders , peripheral blood cytopenia  and renal disorders) .  used and provide a 
listing of the corresponding AESI search table. AESI will b e summarized regardless of study 
drug relationship, by grouping, PT and treatment arm.  
8.3 Serious Adverse Events  
8.3.1 Definitions  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions  
are met (e.g., hospitalization for signs/symptoms of the disease under study, death due to  
progression of disease).  
An SAE is defined as one of the following:  
• Is fatal  
• Is life -threatening  
• Results in patient  hospitalization or prolongation of existing hospitalization  
• Results in a persistent or significant disability/ incapacity  
• Constitutes a congenital anomaly/birth defect  
• Is medically significant, i.e., defined as an event that jeopardizes the patient or may  require 
medical or surgical intervention to prevent one of the outcomes listed above  
• Note that hospitalizations for the following reasons should not be reported as SAEs : 
a. Routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition.  
b. Elective or pre -planned treatment for a pre -existing condition that is unrelated to the  
indication under study and has not worsened since signing the informed consent.  
c. Social reasons and respite care in the absence of any deteriora tion in the patient ’s 
general condition.  
• Note that treatment on an emergency outpatient basis that does not result in hospital  
admission and involves an event not fulfilling any of the definitions of a SAE given above  
is not a n SAE . 
8.3.2 SAE Reporting  
To ensure patient safety, every SAE, regardless of suspected causality, occurring after the subject 
has provided informed consent and until at least 28 days after the patient has stopped study 
treatment must be reported to Kintor /delegated CRO  within 24 hours  of learning of its occurrence.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
59 
 Any SAEs experienced after this 28 -day period should only be reported to Kintor /delegated CRO  
if the investigator suspects a causal relationship to the study treatment. Recurrent episodes, 
complications, or progression of th e initial SAE must be reported as follow -up to the original 
episode within 24 hours of the investigator receiving the follow -up information. An SAE occurring 
at a different time interval or otherwise considered completely unrelated to a previously reported  
one should be reported separately as a new event.  
Information about all SAEs is collected and recorded on the  SAE  Report Form; all applicable 
sections of the form must be completed in order to provide a clinically thorough report. The 
investigator must as sess and record the relationship of each SAE to each specific study treatment 
(if there is more than one study treatment), complete the SAE Report Form in English and submit 
the completed form within 24 hours to Kintor. Detailed instructions regarding the SAE submission 
process and requirements for signatures are to be found in the investigator folder provided to each 
site. 
The Investigator must also promptly notify the Institutional Review Board (IRB) /Independent 
Ethics Committee (IEC) of SAEs, including any follow -up information, in accordance with local 
institutional policy and applicable regulatory requirements. Regulatory authorities will be notified 
of any AE associated with the use of the study drug that is both serious and unexpected, in 
accordance with the appropriate local regulatory guidelines. Notification of the event will be made 
by written, expedited safety report by the Sponsor.  
The Investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by Kintor  to elucidate the nature and/or 
causality of the AE or SAE as fully as possible. This may in clude additional laboratory tests or 
investigations, histopathological examinations, or consultation with other health care professionals.  
Follow -up information is submitted in the same way the original SAE Report. Each re -occurrence, 
complication, or progression of the original event should be reported as a follow -up to that event 
regardless of when it occurs. The follow -up information should describe whether the event has 
resolved or continues, if and how it was treated, whether the b lind was broken or not, and whether 
the patient continued or withdrew from study participation.  
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the Kintor study treat ment, the Kintor Drug Safety 
associate may urgently require further information from the investigator for Health Authority 
reporting. Kintor may need to issue an Investigator Notification (IN), to inform all investigators 
involved in any study with the sam e drug that this SAE has been  reported.  
8.4 Suspected Unexpected Serious Adverse Reactions (SUSARs)  
Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to the 
competent regulatory authorities and relevant IECs  in accordan ce with Directive 2001/20/EC or 
as per national regulatory requirements in participating countries.  
If the SUSAR is fatal or life -threatening, associated with study treatment , and unexpected, 
regulatory authorities and IECs will be notified immediately as per national requirements once the 
Sponsor learns of the event. Additional follow -up (cause of death, autopsy report, and hospital 
report) information should be reported as required . 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
60 
 If the SUSAR is not fatal or life -threatening but is otherwise serious, a ssociated with study 
intervention, and unexpected, regulatory authorities and IECs will be notified as per national 
requirements once  the Sponsor learns of the event.  
The Sponsor will notify the Investigators in a timely fashion of relevant information abo ut 
SUSARs that could adversely affect the safety of subjects . Follow -up information may be 
submitted if necessary.  
The Sponsor will also provide annual safety updates to the regulatory authorities and IECs 
responsible for the study. These updates will incl ude information on SUSARs and other relevant 
safety findings.  
8.5 Emergency Unblinding of Treatment Assignment  
Emergency unblinding should only be undertaken for safety reasons when it is essential for 
effective treatment of the subject. Most often, study treatment discontinuation and knowledge of 
the possible treatment assignments are sufficient to treat a study patient who presents with an 
emergency condition. Emergency code breaks are performed using the IWRS. When the 
investigator contacts the IWRS to u nblind a subject, he/she must provide the requested subject 
identifying information and confirm the necessity to unblind the subject. The investigator will then 
receive details of the drug treatment for the specified subject and a fax  and/ or email (if all owed 
per local regulatory requirement) confirming this information.  The system will automatically 
inform the Kintor monitor for the site and the Study Lead that the code has been broken.  
It is the investigator’s responsibility to ensure that there is a pro cedure in place to allow access to 
the IWRS in case of emergency. The investigator will inform the subject how to contact his/her 
backup in cases of emergency when he/she is unavailable. The protocol number, study treatment 
name if available, subject numbe r and instructions for contacting Kintor (or any entity to which it 
has delegated responsibility for emergency code breaks) will be provided to the subject in case 
emergency unblinding is required at a time when the investigator and backup are unavailable.  
However, if a mechanism is already in place to ensure that the investigator and/or backup can 
always be reached in case of emergency then the procedure above is not required.  
Study treatment must be discontinued once emergency unblinding.  
8.6 Pregnancies  
To ensure subject safety, e ach pregnancy occurring after the start of study treatment  and until 90 
days after the last dose of study drugs  must be reported to Kintor/delegated CRO immediately 
(within 24 hours) of learning of its occurrence.  The subjects who become pregnant during the study 
must be withdrawn.  
The pregnancy will be followed up from the estimated date of delivery plus 3 months to determine 
outcome, including spontaneous  or voluntary termination, details of the birth, and the pr esence or 
absence of any birth defects,  congenital abnormalities, or maternal and/or newborn complications.  
Pregnancy should be reported on a Clinical trial pregnancy form and reported by the investigator 
to Kintor/delegated CRO safety team. Pregnancy foll ow-up should be recorded on the same form 
and should include an assessment of the possible relationship to the investigational treatment of 
any pregnancy outcome. Any SAE experienced during pregnancy must be reported on the SAE 
report form.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
61 
 Details of all pregnancies in female partners of male subjects will be collected after the start of 
study treatment and until 90 days after the last dose of study drugs.  A pregnancy outcome 
informed consent will be provided by Kintor. Consent to report information regard ing these 
pregnancy outcomes should be obtained from the mother.  
Women of childbearing potential should be advised to use highly effective contraception 
methods while they are receiving study treatment and up to 3 months after treatment has been 
stopped.  
If a pregnancy occurs while on study treatment, the newborn will be followed for at least 3 
months.  
If a pregnancy is reported, the investigator should inform the Sponsor  within 24 hours of learning 
of the pregnancy and should inform IRB as well.  
While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be reported as an AE or SAE. 
Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, still birth, congenital 
anomalies, ectopic pregnancy) are considered SAEs.  
8.7 Warnings and Precaution  
No evidence available at the time of the approval of this study protocol indicated that special  
warnings or precautions were appropriate, other than those note d in the provided Investigator  
Brochure  (IB). Additional safety information collected between IB updates will be communicated  
in the form of Investigator Notifications. This information will be included in the subject  informed 
consent and should be discussed with the subject  during the study as needed.  
8.8 Independent Data Monitoring Committee (IDMC)  
An IDMC  will be constituted and will be responsible for monitoring and reviewing the clinical 
study data for safety and e fficacy during the study prior to the final data analysis. To minimize any 
bias introduced  into the analysis of the study results, analysis plans will be finalized and approved 
prior to the interim analyses. The primary goal of the IDMC is to review the in terim results 
regarding the continuing safety of study subject s and the continuing validity and scientific merit 
of the study. Information that may unblind the study during the analyses will not be reported to 
study sites or the blinded study team until th e study has been unblinded. Unblinding details are 
specified in the unblinding plan section of the SAP or in a separate unblinding plan document.   
Responsibilities of the IDMC, communication flow between DMC,  SC, and Kintor, and timing of 
data safety and e fficacy reviews, will be included in the DMC charter document.  
The IDMC will consist of at least 2 COVID -19 experts and one biostatistician and will be formed 
prior to the randomization of the first patient. Detailed recruitment status and interim analysis 
report will be provided to the IDMC. Recruitment will not be interrupted. Details will be provided 
in the IDMC charter.  
It is envisioned that the DMC may make 4 types of recommendations, namely:  
1. No safety or ethical issues, ethical to continue the  study  as planned  
2. Serious safety concerns precluding further study treatment, regardless of efficacy  
3. Ethical to continue the study but recommend an amendment to the protocol  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
62 
 4. Stop prematurely for lack of efficacy  
8.9 Steering Committee  
The SC will be establ ished comprising investigators participating in the study , and Kintor 
representatives from the clinical study  team.  
The SC will be an advisory board for the study according to the protocol through recommending 
modifications as circumstances require. The SC  will be consulted for the protocol amendments as 
appropriate. Together with the clinical study  team, the SC will also develop recommendations  for 
the publications of study results. The details of the role of the SC will be defined in a SC charter. 
The SC will not have access to unblinded study  data.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
63 
 9. DATA COLLECTION AND MANAGEMENT  
9.1 Data Confidentiality  
Prior to any testing under this protocol, including screening tests and assessments, subjects  must 
also provide all authorizations required by local law (e.g., PHI authorization in North America).  
The subject will not be identified by name in the CRF or in  any study reports and these reports 
will be used for research purposes only. Suzhou Kintor Pharmaceuticals , Inc., its partner(s) and 
designee(s), and various government health agencies may inspect the records of this study. Every 
effort will be made to ke ep the subject’s personal medical data confidential.  
Suzhou Kintor Pharmaceuticals , Inc. will protect individual subject information to the fullest 
extent possible during this study . At no time will a subject become identified in any publication or 
presentation.  
However, the subject may have to become identified in the event of a regula tory authority auditor 
inspection in order to verify the accuracy of the data. Access to subject information is at the 
discretion of Suzhou Kintor Pharmaceuticals , Inc. and cannot occur prior to database lock or other 
specified events as determined solely by the discretion of Suzhou Kintor Pharmaceuticals , Inc.  
9.2 Site Monitoring  
At regular intervals during the study, the site will be contacted through monitoring visits  or remote 
monitoring , letters, and telephone calls by a representative to review study progress, Investigator 
and subject compliance with study protocol requirements, and any emergent problems. During 
monitoring visits, the following points will be reviewed in accordance with all applicable 
regulatory requirements and SOPs: original medical records and other source documents, the 
Investigator site file, screening logs, subject informed consent, subject recruitment and follow -up, 
SAE documentation and reporting, documentation and reporting of endpoints, study drug 
allocation, subject complianc e with the study drug regimen, study drug accountability, 
concomitant therapy use, and quality of data. In addition, other required regulatory documents will 
be reviewed, including but not limited to: IRB/IEC composition and correspondence, laboratory 
certification(s), delegation of authority, and Investigator and study personnel curricula vitae.  
9.3 Data Collections  
All data obtained for analysis in the clinical study described in this protocol will be reported in the 
CRF. Data reported in the CRFs should be consistent with and substantiated by the subject’s 
medical record and original source documents. Any discrepancies must be explained. Unless 
explicitly allowed in the CRF instructions, blank data fields are not acceptable. If a field is blank 
because th e item was not done, the field will be marked “Not Done.” If the item is unknown, the 
field will be marked “Unknown.”  
Prior to the start of the study, the Principal Investigator will complete a Delegation of Authority 
form (Site Signature and Delegation Lo g), showing the signatures and handwritten initials of all 
individuals and the delegation of responsibilities, such as identifying those individuals who are 
authorized to make or change entries on CRFs.  
 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
64 
 9.4 Database Management  
A designated CRO will be res ponsible for data management. Data Management will develop a 
Data Management Plan (DMP) document and provide it to Suzhou Kintor Pharmaceuticals, Inc. 
for approval. The DMP document will define all activities in the data collection and cleaning 
process. Th e detailed DMP will be based on the protocol, work scope, contract, analysis plans, 
dataflows , CRFs, data cleaning procedures, other supporting documents, and data management 
standards and practices.  
The programmed data validations will be run to check for  database completeness and consistency, 
and queries will be generated upon data entry or via review by a Clinical Data Manager after entry. 
The sites will respond to the data queries in a timely manner.  
Concurrent medications entered  the database will be coded using a WHO Anatomical Therapeutic 
Chemical dictionary. Coexistent diseases and AEs will be coded using MedDRA.  
9.5 Quality Control  
The Sponsor or its designee will perform the quality assurance and quality control activities of  this 
study; however, responsibility for the accuracy, completeness, and reliability of the study data 
presented to the Sponsor lies with the Investigator generating the data.  
The Sponsor  will arrange audits as part of the implementation  of quality assuran ce to ensure that 
the study is being conducted in compliance with the protocol, Standard Operating Procedures, 
GCP, and all applicable regulatory requirements.  Audits will be independent of and separate from 
the routine monitoring and quality control funct ions.  Quality assurance procedures will be 
performed at study sites and during data management to assure that safety and efficacy data are 
adequate and well documented.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
65 
 10. STATISTICAL METHODS AND DATA ANALYSIS  
10.1 General Considerations  
It is pl anned that the data from all centers participating in the study  will be combined, so that an 
adequate number of patients are available for analysis. Kintor and/or a designated CRO will 
perform all analyses. And data analyses performed independently by any investigator should be 
submitted to Kintor before publication or presentation.  
A Statistical Analysis Plan (SAP) will be prepared after the protocol is approved. It will provide 
further details regarding the definition of analysis variables and analysis me thodology to address 
all study objectives. The SAP will serve as a compliment to the protocol and supersedes it in case 
of differences.  
The statistical evaluation will be performed using the Statistical Analysis Software (SAS®) 
Version 9.4 or higher (SAS Institute, Cary, NC). All data will be listed, and summary tables will 
be provided. Summary statistics will be presented by dose group. For continuous variables, data 
will be summarized with the number of subjects (N), mean, standard deviation, median, min imum, 
and maximum by treatment group. For categorical variables, data will be tabulated with the 
number and percentages of subjects for each category by treatment group.  
Interim Analysis will be conducted based on the Data Monitoring Committee SAP.  
10.2 Analysis Sets  
10.2.1 Intent -to-Treat Analysis Set  (ITT)  
The intent -to-treat analysis set includes all randomized subjects.  
10.2.2 Modified Intent -to-Treat Analysis Set (mITT)  
The mITT analysis set includes all randomized subjects who have received at least one dose of 
the study treatment. The primary efficacy analysis will be conducted on the mITT  Analysis Set.  
10.2.3 Safety Analysis Set (SS) 
The safety analysis set includes all subjects with at least one dose of study medication. The 
disposition, study summary, and safety analysis will be conducted on Safety Analysis Set.  
10.2.4 Per-Protocol Analysis Set (PPS)  
The per -protocol analysis set includes all ITT subjects without major protocol violations. The 
per-protocol analysis set wi ll be defined under classification specification prior to unblinding of 
the study treatment code.  
10.2.5 Pharmacokinetic Analyses  
Pharmacokinetic analyses will be conducted on data from at least 100  subject s who receive  
intervention and have evaluable PK.  
 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
66 
 10.3 Subject  Demographics /Other Baseline Characteristics  
Demographics  and other baseline data including age, age group, race, ethnicity, BMI, baseline 
disease, u nderlying medical conditions 0, 1 -2, ≥3 (as defined in Section 4.1.1 .), and other disease 
characteristics will be summarized  descriptively by treatment group using data from the ITT . 
Categori cal data will be presented as frequencies and percentage s and if appropriate their  95% 
confidence intervals . For continuous data, mean, standard deviation, median, 25th and 75th 
percentiles, minimum, and maximum will be presented.  
10.4 Treatments ( Study Treatment , Concomitant Therapies , Compliance ) 
The safety set will be used for the analyses below.  
The actual dose and duration of GT0918, as well as dose intensity  (computed as the ratio of 
actual dose received to actual duration) and the relative dose intensity  (computed as the ratio of 
the dose intensity to planned dose received/plann ed duration), will be listed and summarized 
using descriptive statistics. The total daily doses of GT0918 for each patient will be summarized 
using descriptive statistics ( e.g., mean, median, and mode).  
Concomitant medications and significant non -drug the rapies will be listed by patient and 
summarized by ATC (Anatomical Therapeutic Chemical classification system) term for each 
treatment group.  These summaries will include medications starting on or after the start of study 
treatment or medications starting  prior to the start of study treatment and continuing after the 
start of study treatment. Any prior concomitant medications or significant non -drug therapies 
starting and ending prior to the start of study treatment will be listed.  
Compliance to the study drug will be assessed by the investigator and/or study personnel at each 
patient visit and information provided by the patient and/or caregiver in the drug accountability 
form including dosages administered, dosing intervals, dose changes or interruptions with 
associated reasons . 
10.5 Efficacy Analysis  
10.5.1 Primary Efficacy Objective  
The primary objective is to evaluate the efficacy of GT0918 in subjects with mild to moderate 
COVID -19 illness.  
10.5.1.1  Primary Efficacy Variable  
The primary efficacy endpoint is the proportion of subjects  who do not experience any of the 
following events due to all causes by Day 28:  
• Hospitalization for ≥ 24 hours  
• Supplemental oxygen for ≥24 hours in response to SpO2 ≤93%  
• Death  
10.5.1.2  Statistica l Hypothesis, Model, and Method of Analysis  
Primary Null Hypothesis H0: proportion of subject s who do not  experience all-cause 
hospitalization  (defined as ≥24 hours ) and do not  require supplemental oxygen for ≥24h in 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
67 
 response to SpO 2≤93% and are alive  by Day 28  in the GT0918 arm (p1) is equal to the 
proportion in the placebo arm (p2) 
Primary Alternative Hypothesis H a: the proportion of subject s who do not experience all-cause 
hospitalization  (defined as ≥24 hours ) and do not r equire supplemental oxygen for ≥24h in 
response to SpO 2≤93% and are alive  by Day 28  in GT0918 arm (p1) is less than the proportion 
in the placebo arm 2  (p2)  
Mathematically written as:  
H0: p1 - p2= 0  
Ha: p1 - p2>0 
The primary endpoint event rate will be compared between treatment and placebo arm using 
Cochran –Mantel –Haenszel (CMH) chi-square  test using the stratification factors at time of 
randomization at the one-sided 0.0 25 level based on mITT. P-values and 95%  exact confidence 
intervals for the treatment difference will be presented.  
10.5.1.3  Handling of Dropouts, M issing Values/ Censoring/ Discontinuations  
No dropouts will be replaced. Every effort will be made to avoid missing data. All subjects will 
be followed fully  in the trial whenever possible . All patients who maintain consent to be 
followed for additional outcome information should remain in the study through the end of the 
double -blind period for all important safety and efficacy assessments. The only reasons f or study 
withdrawal should be withdrawal of consent and loss to follow -up. To  help prevent missing data, 
The following reinforcement will be taken : (1) the protocols and informed consent forms clearly 
differentiate treatment discontinuation from study with drawal; (2) site investigators be trained 
about the importance of retention and steps to prevent missing data; (3) the consent forms 
include a statement educating patients about the continued scientific importance of their data 
even if they discontinue stu dy treatment early; and (4) continue following patients after 
discharge via telehealth visits or other approaches (e.g., telephone calls, texts, and emails to the 
patient and close contacts); and (5) steps  will be taken  to ascertain vital status in all ran domized  
patients.  
The extra effort to contact all subjects specifically those who discontinued treatment early to 
assess the occurrence of any component of the primary endpoint, hospitalization, need for 
oxygen, or death by day 28 will minimize missing dat a for the primary endpoint. For the primary 
analysis of the primary endpoint , patients with missing primary assessments will be included in 
the analysis and evaluated  as treatment failures.  Sensitivity analyses will be considered e.g. per 
protocol set anal ysis and complete case analysis  (i.e. patients with non-missing primary 
assessments ).  
 
 The SoA, outlined in the protocol, specifies the allowable windows for assessments. 
Assessments performed outside these windows will not be excluded from any analysis but may 
not be reported as a protocol deviation.  
Further d etails for handling missing data will be specified in the SAP  and appropriate sensitivity 
analyses specified .  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
68 
 10.5.1.4  Subgroup Analyses  
This study is not powered for subgroup analyses; therefore, all subgroup analyses will be treated 
as exploratory.  
Subgroup analyses will be conducted for the primary endpoint  and displayed graphically in 
forest plots . Subgroups may include : 
o time from symptom onset to study randomization  
o geographic region  
o baseline severity of COVID -19 
o age group   
o sex 
o race 
o ethnicity  
o baseline BMI  
o concomitant medication of interest use (yes/no)  
o strata used at time of randomization  (number of risk factors)  
o vaccination status  
10.5.1.5  Sensitivity  Analyses  
Sensitivity analysis o f the primary endpoint analysis will be conducted. Details will be specified 
in the SAP. 
10.5.2 Secondary Objectives Variables  
10.5.2.1 Hospitalization percentage  
The percentage of subjects w ith all-cause and COVID -19 related hospitalization (defined as ≥24 
hours) or requirement for supplemental oxygen for ≥24h in response to SpO 2≤93% or death by 
Day 28  will be analyzed . 
The proportion of subject s that experience hospitalization, supplemental oxygen , emergency room 
visit or death by Day 28 will be summarized by treatment in frequency tables and listed.  
The total number of all-cause and COVID -19 related hospitalization and days of hospitalization 
due to all cause s and COVID -19, will be summarized based  on mITT. 
 
10.5.2 .2 COVID -19 Ordinal Outcomes Scale   
The percentage of subjects at each clinical status using NIAID ordinal scale at Days 7, 14, and 
28 will be analyzed.  
1. Death  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
69 
 2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation 
(ECMO)  
3. Hospitalized, on non -invasive ventilation or high flow oxygen devices  
4. Hospitalized, requiring supplemental oxygen  
5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care 
(COVID -19-related or other medica l conditions  preventing hospital discharge ) 
6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care  
7. Not hospitalized, limitation on activities and/or requiring home oxygen  
8. Not hospitalized, no limitations on activities  
Mean value by treatment group will be plotted over time.  
Comparison of the mean worst daily NIAID  ordinal scale values by Days 7, 1 4, and 2 8. The 
worst ordinal scale will be fitted by a proportional odds model with treatment, age, sex, baseline 
severity  and number of risk factors as covariates.  
In addition, proportion of subjects worsening from baseline will be presented, where  worsening 
is defined as the proportion of subjects  with any worsening on the NIAID ordinal scale from 
baseline to Days 7, 14, and 28.  
The following events (observed at any time point during the study treatment period) will be 
summarized:  
o Proportion of subject s hospitalized  
o Duration of hospitalization (DOH; in days)  
o Proportion (percentage) of subject s admitted to ICU  
All hospitalization events will be listed.  
 
10.5.2.3 Proportion of Symptom resolution  
For each symptom resolution is defined as absent for at least 48 hours. The proportion of 
subjects with symptom resolution will be analyzed by symptom.  
All s ymptom resolution is defined as all symptoms (those scored 0 -3) on the symptom 
questionnaire scored as absent.  The proportion of subjects with all symptom resolution will be 
analyzed .  
These analyses will be performed at Days 7, 14, and 28 by treatment in frequency tables and 
listed.  
In addition, the number of participants that achieve symptom resolution at Days 7, 14, and 2 8 
will be analyzed using logistic regression to compare GT0918  versus placebo if there are 
sufficient data available.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
70 
 10.5. 2.4 Time to symptom resolution   
Time to all symptom resolution is defined (in days) as:  
First study day when symptom resolution status is changed to “Yes” – first dosing Date + 1 . 
If a patient has not experienced symptom resolution by completion or early discontinuation of 
study/study treatment, the patient will be censored at the date of the ir last visit during the 
treatment period.  
Time to symptom resolution will be evaluated up to Day 28  and will be summarized by treatment 
and listed. Cox proportional hazard model will be used, stratified by  duration since symptom 
onset to randomization category.  
Time to symptom resolution will be presented graphically.  
10.5. 2.5 Symptom Improvement  
10.5.2.5.1 Proportion of subjects demonstrating symptom improvement via the symptom 
questionnaire on Days 3, 7,  14 and 28. 
Symptom improvement is defined as a change in severity  of total ratings  from a higher score to a 
lower score which is defined as following:  
• symptoms scored as moderate or severe at baseline are scored as mild or absent,  
OR 
• symptoms scored as mild or absent at baseline are scored as absent.  
The proportion of subject s that achieve symptom improvement at Days 7, 11, 14 and 28  will be 
summarized by treatment in frequency tables and listed.  
10.5. 2.6 Time to Symptom Improvement  
Time to symptom improvement is defined (in days) as:  
(Date when symptom improvement status is changed to “Yes” – first dosing Date + 1) . 
If a subject  has not experienced symptom improvement by completion or early discontinuation 
of study/study treatment, the patient will be censored at the date of their last visit during the 
treatment period.  
Time to symptom improvement will be evaluated up to Day 28  and will be summarized by 
treatment and listed. In addition, a graphical presentation of the symptom improvement will be 
provided using a KM plot.  
10.5. 2.7 Virus Clearance  
Proportion of subjects that achieve SARS -CoV -2 clearance at Days 3, 7, 14 and 28. 
The proportion of subject s that achieve SARS -CoV -2 clearance at Days 3, 7, 14, and 28 will be 
summarized by treatment in frequency tables and listed.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
71 
 10.5. 2.8 Time to SARS -CoV -2 clearance  
Time to SARS -CoV -2 clearance will be evaluated by day 28  and will be summarized by 
treatment and listed.   
Time to SARS -CoV -2 clearance will be presented graphically.  
10.5.2.9 V iral load reduction  
SARS -CoV -2 viral load, including changes from baseline, will be summarized and plotted by 
treatment and listed. Baseline is defined as the Day 1 pre -dose assessment. Changes from 
baseline to Day 3, 7,  14 and 28 in SARS -CoV -2 viral load data in the log base 10 scale will be 
analyzed using a linear mixed -effect model.  
The AUC from Day 1 pre -dose to Day 28 (AUC[0 -D28]) will be calculated according to the 
linear trapezoidal rule using the measured SARS -CoV -2 viral load -time values above the lower 
limit of quantification. No imputations of missing data will be conducted. No AUC(0 -D28) 
values will be calculated when Day 1 pre -dose and/or Day 28 values are missing, or if there are 
more than 3 values missing in the profile.  
The AUC (0 -D28) will be summarized and plotted by treatment and listed.  
 
10.6 Exploratory Objectives  
10.6.1 Pharmacokinetics of GT0918   
PK concentrations of GT0918 (and any re levant metabolites such as GT0955) will be 
summarized by time point using descriptive statistics by treatment only for GT0918 arm. All PK 
concentration data will be listed as appropriate  
Data handling principles  
Plasma samples may be assayed for GT0918 con centrations by Kintor or Kintor  designated 
laboratory. The  PK data may be analyzed using validated LC -MS/MS methods with a LLOQ of 
approximately  5.00 ng/mL for GT0918 . 
All concentrations below the LLOQ will be displayed in listings as zero with a flag and  handled 
as zero in any calculations of summary statistics, but handled as missing for the  calculation of the 
geometric means and their CV. Any missing PK parameter data will not to  be imputed.  
10.6.2 Viral resistance to GT0918  
If appropriate, the evaluation of viral resistance will be conducted as described in a separate  
bioanalytical analysis plan.  Comparison from baseline to the last evaluable time point up to Day  28 
on the emergence of viral resistance to GT0918 . 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
72 
 10.7 Safety Analysis  
10.7.1 Anal ysis set and grouping for the analyses  
For all safety analyses, the safety set will be used. All listings and tables will be presented by  
treatment group.  
The overall observation period will be divided into 3 mutually exclusive segments:  
1. pre -treatment period: from day of patient ’s informed consent to the day before first dose  of study 
medication  
2. on -treatment period: from  D 1 (the day of first dose of s tudy drug) to D 14 (the day of last dose)  
3. post-treatment period: from D 15 (the day after last dose)  to D 28 (14  days after last dose ) 
4. safety follow up  period: from D 28 (14 days after last dose)  to D 42 ( 28 days after last dose ) 
10.7.2. Adverse events  
Summary tables for AEs have to include only AEs that started or worsened  during the on -treatment 
period, the treatment -emergent AEs. However, all safety data  (including those from the pre and 
post-treatment periods) will be listed and those  collected  during the pre -treatment and post -
treatment period are to be flagged.  
The incidence of TEAEs  (new or worsening from baseline) will be  summarized by system organ 
class and or preferred term, severity (based on DAIDS  grades),  type of AE, relation to study 
treatment by treatment group.  
In an overview table, the number and percentage of subject s who experienced a TEAE,  SAE, AE 
related to study drug, death due to an AE, discontinued from the study treatment, or discontinued 
from the study due to an AE  will be summarized by treatment.  
Treatment -emergent AEs may be reported separately for the treatment period and follow -up 
periods.  
10.7.3 Laboratory abnormalities  
For laboratory tests covered by DAIDS  Version 2.1 , a Grade 0 will be assigned for all non -missing 
values not graded as 1 or higher.  
For laboratory tests where grades are not defined by DAIDS , results will be graded by the  
low/normal/high classifications based on laboratory normal ranges.  
The following by  treatment summaries will be generated separately for hematology,  biochemistry,  
and coagulation  laboratory tests:  
• Frequency table for newly occurring on -treatment Grades 3 or 4 . 
• Shift tables using DAIDS  grades to compare baseline to the worst on -treatment value . 
• For laboratory tests w here DAIDS  grades are not defined, shift tables using the  
low/normal/high  classification to compare baseline to the worst on -treatment value.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
73 
 • Listing of all laboratory data with values flagged to show the corresponding DAIDS  grades 
and the classifications relative to the laboratory normal ranges.  
In addition to the above -mentioned  tables and listings, other exploratory analyses, for example  
figures plotting time course of raw or change in laboratory tests over time or box plots might  be 
specified in the ana lysis plan.  
10.7.4 Other safety data  
10.7.4.1 Vital signs  
• Shift table from baseline to worst on -treatment result . 
• Table with descriptive statistics at baseline, one or several post -baseline time points and  
change from baseline to this/these post-baseline time points.  
10.7.4.2 Tolerability  
Tolerability will be studied in terms of dose discontinuation  due to AE.  
Reasons for dose discontinuation  will be listed and summarized by treatment.  
10.8 Interim Analysis  
An interim analysis will be conducted when 334 subjects completed Day 28 after first dose. The 
objective of the interim analysis to assess safety, futility, efficacy, sample size adjustment as well 
as potential enrichment of the population to enroll a popu lation at higher risk for an infection 
requiring hospitalization or oxygen support in case the observed rates for the primary endpoint in 
the control arm are lower than expected. An independent data  monitoring committee (IDMC) 
will review the unblinded int erim analysis report to assess the objectives of the interim analysis 
and provide recommendations about early study closure, change study population, or change to 
study sample size.  Rigorous s teps will be taken  (e.g., firewalls)  where possible to minimize the 
information that can be inferred by observers.  
The futility criterion for the study will be based on the conditional power of the study being <10%. 
The efficacy criterion will be based on the one -sided p -value of the primary endpoint analysis as 
<0.001 5. In this case the stopping boundary for efficacy is met and the study could be stopped for 
efficacy.  
The topline safety analysis will include treatment related SAE including death. The IDMC can 
recommend stopping the study.  
The conditional power will be  evaluated based on primary endpoint in the interim analysis. I DMC 
could recommend a change of the subject population to enroll  more subjects if the event rate is 
lower than expected . The IDMC will review the interim efficacy results and in case of substantial 
treatment differences between subpopulations, e.g., <50 years compared to ≥50 years, provide 
recommendations for modifications of further enrollment. Criteria for those recommendations will 
be defined in the DMC charter. The consequences of tho se recommendations on the statistical 
analysis as well as the  samples size adjustment will be summarized in a separate document and 
attached to the statistical analysis plan.  
If the conditional power of the study at the time interim analysis is between 50 % to 80% (promising 
zone approach), the sample size could be increased to a maximum of 1500 subjects based on the 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
74 
 efficacy in the interim analysis for overall population. If the conditional power of the study is 
above 80% power the sample size will not be changed. The detailed exact rule for sample size re -
estimation will be pre -specified in the DMC charter.  
Assuming there is no change in the study design regarding sample size modification, the p -value 
of 0.0245 will be used to conclude the efficacy of the treatment arm. O'Brien -Fleming Alpha 
Spending Function was used to calculate the efficacy boundary and the resulting alpha levels for 
the interim analysis and the final analysis.  
10.9 Sample Size Calculation  
The primary endpoint event rate for the treatme nt arm is assumed at 97 % and  for the placebo 
arm is assumed at 9 1%.  
The sample size was calculated using EAST v6.5 for a group sequential test for 2 proportions. 
With a total of 668 subjects the study will have 90% power at a one -sided 0.025 significance 
level of the hospitalization or death rate using a Chi -square test with one interim analysis at 50% 
of the information (when 334 subjects have been observed for 28 days) . 
 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
75 
 11. ETHICAL CONSIDERATIONS AND ADMINISTRATIVE 
PROCEDURES  
11.1 Regulatory and Ethical Compliance  
This study will be conducted in accordance with the protocol and with the following:  
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines.  
• Applicable International Council for Harmonization (ICH) Good Clinical Practice (GCP) 
Guidelines, and  
• Applicable laws and reg ulations.  
The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant documents 
(e.g., advertisements) must be submitted to an IRB/IEC by the investigator and reviewed and 
approved by the IRB/IEC before the study is initiated.  
Any am endments to the protocol will require IRB/IEC approval before implementation of changes 
made to the study design, except for changes necessary to eliminate an immediate hazard to study 
subject s. 
The investigator will be responsible for the following:  
• Provi ding written summaries of the status of the study to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB/IEC . 
• Notifying the IRB/IEC of SAEs or other significant safety findings as req uired by 
IRB/IEC procedures, and  
• Providing oversight of the conduct of the study at the site and adherence to requirements 
of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical 
studies (if applicable), and all other applicable l ocal regulations.  
Investigator sites are compensated for participation in the study as detailed in the clinical study  
agreement.  
11.2 Responsibilities of the Investigator and IRB/IEC/REB  
All subject data relating to the study will be recorded on printed or  electronic CRF unless  
transmitted to the Sponsor  or designee electronically (e.g., laboratory data). The investigator is  
responsible for verifying that data entries are accurate and correct by physically or electronically  
signing the CRF.  
The investigator must permit study -related monitoring, audits, IRB/IEC review, and regulatory  
agency inspections and provide direct access to source data documents.  
 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
76 
 11.3 Informed Consent Procedures  
For each study subject, written informed consent will be obta ined prior to any protocol -related 
activities.  As part of this procedure, the Principal Investigator or one of his/her associates must 
explain orally and in writing the nature, duration, and purpose of the study, and the action of the 
drug in such a manner  that the subject is aware of the potential risks, inconveniences, or adverse 
effects that may occur.  The subject should be informed that he/she may withdraw from the study 
at any time, and the subject will receive all information that is required by local  regulations and 
ICH guidelines.  The investigator  will provide the Sponsor or its representative with a copy of the 
IRB/IEC -approved ICF prior to the start of the study.  
Should changes to the Informed Consent form become necessary during the study, the investigator  
will ensure that the changes are approved by the Sponsor  or its representative prior to submission 
to the IRB.  All revisions of the protocol must be reflected in the IC F, if applicable, and reviewed 
by the IRB. Subjects must be made aware of thos e applicable changes in the protocol and must 
consent to participate in the revised protocol.  
11.4 Discontinuation of the Study  
Discontinuation of specific sites or of the study  as a whole are handled as part of regulatory, ethical, 
and study  oversight considerations. In rare instances, it may be necessary for a subject  to 
permanently discontinue (definitive discontinuation) study intervention.  
11.5 Publication of Study Protocol and Results  
Both the use of data and the publication policy are detailed within the clinical study agreement.  
Intellectual property rights (and related matters) generated by the Investigator and others 
performing the clinical study will be subject  to the terms of a clinical study agreement that will be 
agreed between the Institution and the Sponsor or their designee.  With respect to such rights, the 
Sponsor or its designee will solely own all rights and interests in any materials, data, and 
intelle ctual property rights developed by Investigators and others performing the clinical study 
described in this protocol, subject to the terms of any such agreement. In order to facilitate such 
ownership, Investigators will be required to assign all such inven tions either to their Institution or 
directly to the Sponsor or its designee, as will be set forth in the clinical study agreement.  
  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
77 
 11.6 Study Documentation, Record Keeping and Retention of Documents  
The Investigator must maintain all study documentation  as confidential and  take measures to 
prevent accidental or premature destruction of these documents.  
The Investigator must retain the study documents at least 2 years after the last approval of a 
marketing application/new drug application for the indicati on investigated or at least 2 years have 
elapsed since the formal discontinuation of clinical development of the investigational product 
(e.g., the Investigational New Drug application is withdrawn). These documents should be retained 
for a longer period, however, if required by the applicable regulatory requirements or by an 
agreement with Suzhou Kintor Pharmaceuticals, Inc.  
The Investigator must notify Suzhou Kintor Pharmaceuticals, Inc. prior to destroying any study 
essential documents.  
If the Investigat or can no longer ensure archiving, he/she shall inform Suzhou Kintor 
Pharmaceuticals, Inc. The relevant records shall be transferred to a mutually agreed upon designee.  
11.7 Source Documents  
Source documents provide evidence for the existence of the subject  and substantiate the integrity 
of the data collected. Source documents are filed at the Investigator’s site.  
Data reported in the eCRF that are transcribed from source documents must be consistent with the 
source documents or the discrepancies must  be explained. The Investigator may need to request 
previous medical records or transfer records, depending on the study. Also, current medical records 
must be available.  
The Investigator must maintain accurate documentation (source data) that supports the  information 
entered in the eCRF.  
Study monitors will perform ongoing source data verification to confirm that data entered into the 
eCRF by authorized site personnel are accurate, complete, and verifiable from source documents; 
that the safety and rights of participants are being protected; and that the study is being conducted 
in accordance with the currently approved protocol and any other study agreements, ICH GCP, 
and all applicable regulatory requirements.  
11.8 Confidentiality of Study Documents and Subject  Records  
All communications, reports, and subject samples will be identified by site number, and a code 
number and/or initials to maintain subject confidentiality. All records will be kept confidential to 
the extent permitted by law. If a waiver or authorization separate from the statement in the 
Informed Consent is required for permitting access to a subject’s medical records (e.g. HIPAA), 
the Investigator will obtain such authorization prior to enrolling a subject in the study. The 
investigator  should keep a separate log of subjects, codes, names, and addresses. Documents which 
identify the subject by name (for example, the ICF) should be kept in strict confidence.  
The Sponsor  and its business associates agree to keep all subject information confide ntial. Data 
resulting from analyses will be entered into a database that is not accessible to the public. Subject 
data will be identified only by the subject screen number, randomization number and initials, and 
not by any other annotation or identifying i nformation.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
78 
 The Sponsor  and its business associates will take every possible step to reduce the risk of releasing 
information to the public that would enable subjects to be personally identified.  
11.9 Audits and Inspections  
Suzhou Kintor Pharmaceuticals,  Inc.’s Quality Assurance Unit (or representative) may conduct 
audits at the study site(s). Audits will include, but are not limited to: drug supply, presence of 
required documents, the informed consent process, laboratory specimen processing, and 
comparis on of CRFs with source documents. The Investigator agrees to cooperate with audits 
conducted at a reasonable time and in a reasonable manner.  
Regulatory authorities worldwide may also audit the Investigator during or after the study. The 
Investigator shoul d contact Suzhou Kintor Pharmaceuticals, Inc. immediately if this occurs, and 
must fully cooperate with the audits conducted at a reasonable time in a reasonable manner.  
The Investigator is required to make all study documentation promptly available for in spection, 
review or audit at the study site upon request by Sponsor , its representatives, or any appropriate 
regulatory agencies.  
11.10 Financial Disclosures  
Prior to the study commencing, the Sponsor (or its designee) and the Investigator (or the institut ion, 
as applicable) will agree on costs necessary to perform the study.  This agreement will be 
documented in a financial agreement that will be signed by the Investigator (or the institution 
signatory) and the Sponsor (or its designee).  
The Investigator is required to have adequate current insurance to cover claims for negligence 
and/or malpractice.  The Sponsor will provide insurance coverage for the clinical study as required 
by national regulations.  
 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
79 
 12. PROTOCOL ADHERENCE  
The Investigator will not make any changes to this protocol without prior written consent from the 
Sponsor  Suzhou Kintor Pharmaceuticals, Inc. and subsequent approval by the IRB/IEC. Any 
permanent change to the protocol, whether it is an overall change or a change for specific study 
center(s), must be handled as a protocol amendment. Any amendment to the protocol that appears 
necessary as the study progresses will be fully discussed by the Investigator(s) and Suzhou Kintor 
Pharmaceuticals, Inc. If agreement  is reached regarding the need for an amendment, it will be 
written by Suzhou Kintor Pharmaceuticals, Inc. The written amendment must be submitted to the 
chairman of the IRB/IEC identified with this responsibility. Except for administrative amendments, 
Investigators must await IRB/IEC approval of protocol amendments before implementing the 
change(s).  
Administrative amendments are defined as having no effect on the safety of the research subjects, 
scope of the investigation, or quality of the study . However,  a protocol change intended to 
eliminate an apparent immediate hazard to subjects should be implemented immediately, and the 
IRB/IEC notified within 5 days. Suzhou Kintor Pharmaceuticals, Inc. will ensure submission of 
any protocol amendments to the approp riate regulatory agencies.  
When, in the judgment of the chairman of the local IRB/IEC, the Investigators, and/or Suzhou 
Kintor Pharmaceuticals, Inc., the amendment to the protocol substantially alters the study design 
and/or increases the potential risk to  the subject; the currently approved written ICF will require 
similar modification. In such cases, the Investigator will obtain repeat informed consent from 
subjects enrolled in the study before expecting continued participation.   
 
 
 
  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
80 
 13. REFERENCES  
Hoffmann M, Kleine -Weber H, Schroeder S, Krü ger N, Herrier T, Erichsen S, Schiergens TS, 
Herrler G, Wu NH, Nitsche A, Mü ller M, Drosten C, Pö hlmann, S. n.d.  
C., Jennison, and B. W. Turnbull. 2000. Group Sequential Methods with Applications to Clinical 
Trials.   
Damien A. Leach, Ana -Maria Isac, Charlotte L. Bevan, Greg N. Brooke. 2020. "TMPRSS2, 
required for SARS -CoV -2 entry, is downregulated in lung cells by enzalutamide, a prostate 
cancer therapeutic." research square.   
2017. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse 
Events.  July. https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf.  
LAN, K. K. GORDON, and DAVID L. DEMETS. 1983. "Discrete Sequential Boundaries for  
Clinical Trials." Source: Biometrika  659-663. 
Maria Schroeder, Berfin Tuku, Dominik Jarczak,. 2020. "The majority of male patients with 
COVID -19 present low testosterone levels on admission to Intensive Care in Hamburg, 
Germany: a retrospective cohort stu dy." medRxiv.   
Markus Hoffmann, Hannah Kleine -Weber, Simon Schroeder, Marcel A. Mü ller. 2020. "SARS -
CoV -2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven 
Protease Inhibitor." Cell 271-280. 
Reboussin, D.M., D.L. DeMets, K Kim, a nd K.K.G and Lan. 2000. "Computations for Group 
Sequential Boundaries Using the Lan -DeMets Spending Function Method." Controlled 
Clinical Trials  190-207. 
Tie Zhoua, Weidong Xua, Wei Zhang, Ye Sun, Hong hua Yan, Xu Gao,. 2020. "Preclinical profile 
and phase  I clinical trial of a novel androgen receptor antagonist GT0918 in castration -
resistant prostate cancer." European Journal of Cancer  29-40. 
Wei-Jie Guan, Zheng -Yi Ni, Yu Hu, Wen -Hua Liang. 2020. "Clinical Characteristics of 
Coronavirus Disease 2019 in Chi na. ." The new england journal o f medicine  1708 -1720.  
Youzhi Tong, Chunyun Chen, Juan Wu, Jiangtao Yang, Huihui Zhang. 2014. "Proxalutamide 
(GT0918), a potent androgen receptor pathway inhibitor." AACR Annual Meeting 2014.  
San Diego, USA, CA.  
Yuanyuan Qiaoa, Xiao -Ming Wanga. 2021. "Targeting transcriptional regulation of SARS -CoV -
2 entry factors ACE2 and TMPRSS2." PNAS.  
https://www.pnas.org/content/118/1/e2021450118.  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
81 
  
14.APPENDICES  
Appendix 1. Drugs that Should Be Used Cautiously with GT0918  
 
  Strong Inhibitors  Moderate Inhibitors  Weak Inhibitors  
CYP3A4  boceprevir, 
cobicistat(h),  danoprevir and 
ritonavir(j), elvitegravir and 
ritonavir(j), grapefruit 
juice(k), indinavir and 
ritonavir(j), itraconazole(h), 
ketoconazole, lopinavir and 
ritonavir(h,j), paritaprevir 
and ritonavir and (ombitasvir 
and/or dasabuvir)(j), 
posaconazole, ritonavir(h,j), 
saquinavir and ritonavir(h,j), 
telaprevir(h), tipranavir and 
ritonavir(h,j), 
telithromycin,  troleandomyci
n, voriconaz ole aprepitant,  ciprofloxacin,  co
nivaptan(l), crizotinib, 
cyclosporine, diltiazem(m), 
dronedarone(h), 
erythromycin, 
fluconazole(f), 
fluvoxamine(a), imatinib, 
tofisopam, verapamil(h)  chlorzoxazone, 
cilostazol, cimetidine, 
clotrimazole, 
fosaprepitant, 
istrad efylline, 
ivacaftor(h), 
lomitapide, 
ranitidine, 
ranolazine(h),  ticagrel
or(h)  
  clarithromycin(h),  idelalisib, 
nefazodone, nelfinavir(h)   -  - 
CYP2C8  gemfibrozil(e)  clopidogrel(b), deferasirox, 
teriflunomide  trimethoprim  
  Strong Inducers  Moderate Inducers  Weak Inducers  
CYP3A  apalutamide, 
carbamazepine(e), 
enzalutamide(g), mitotane, 
phenytoin(b), rifampin(a), 
St. John’s wort(h)  bosentan, efavirenz(f), 
etravirine, phenobarbital, 
primidone  armodafinil, 
modafinil(i), 
rufinamide  
CYP2C8  - rifampin(a)  - 
 
 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
82 
  
  Sensitive Substrates  Moderate Sensitive Substrates  
CYP2D6  atomoxetine, desipramine, 
dextromethorphan, eliglustat(e), 
nebivolol, nortriptyline, 
perphenazine, tolterodine, R -
venlafaxine  encainide, imipramine, metoprolol, 
propafenone, propranolol, tramadol, 
trimipramine, S -venlafaxine  
CYP2C8  repaglinide(b)  montelukast, pioglitazone, 
rosiglitazone  
CYP2C9  celecoxib(c)  glimepiride, phenytoin, tolbutamide, 
warfarin  
CYP2C19  S-mephenytoin, omeprazole  diazepam, lansoprazole(d), 
rabeprazole, voriconazole  
CYP3A4  alfentanil, avanafil, buspirone, 
conivaptan, darifenacin, 
darunavir(f), ebastine, 
everolimus, ibrutinib, lomitapide, 
lovastatin(g), midazolam, 
naloxegol, nisoldipine, 
saquinavir(f), simvastatin(g), 
sirolimus, tacrolimus, 
tipranavir(f), triazolam, vardenafil  alprazolam, aprepitant, atorvastatin(c), 
colchicine, eliglustat(e), pimozide, 
rilpivirine, rivaroxaban, tadalafil  
  budesonide, dasatinib, 
dronedarone, eletriptan, 
eplerenone, felodipine, 
indinavir(f), lurasidone, 
maraviroc, quetiapine, sildenafil, 
ticagrelor, tolvaptan    
 
 
 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
83 
 Appendix 2. Common COVID -19-Related Symptoms   
Example of an Assessment of 14 Common COVID -19-Related Symptoms: Items and Response 
Options  
Example items  
For items 1 –10, sample item wording could be: “What 
was the severity of your [insert symptom] at its worst 
over the last 24 hours?”  Example response options  
and scoring* * 
1. Stuffy or runny nose  None = 0  
Mild = 1  
Moderate = 2  
Severe = 3  2. Sore throat  
3. Shortness of breath (difficulty breathing)  
4. Cough  
5. Low energy or tiredness  
6. Muscle or body aches  
7. Headache  
8. Chills or shivering  
9. Feeling hot or feverish  
10. Nausea (feeling like you wanted to throw up)  
11. How many times did you vomit (throw up) in the last 
24 hours? *  I did not vomit at all = 0  
1–2 times = 1  
3–4 times = 2  
5 or more times = 3  
12. How many times did you have diarrhea (loose or 
watery stools) in the last 24 hours? *  I did not have diarrhea at all = 0  
1–2 times = 1  
3–4 times = 2  
5 or more times = 3  
13. Rate your sense of smell in the last 24 hours  My sense of smell is THE 
SAME AS usual = 0  
My sense of smell is LESS 
THAN usual = 1  
I have NO sense of smell = 2  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
84 
 14. Rate your sense of taste in the last 24 hours  My sense of taste is THE SAME 
AS usual = 0  
My sense of taste is LESS 
THAN usual = 1  
I have NO sense of taste = 2  
*Assessing COVID -19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of 
Drugs and Biological Products for COVID -19 Prevention or Treatment  
Guidance for Industry  
** The response options shown for items 11 and 12 are intended only for use with a 24 -hour recall period.  
 
Referen ce to Appendix 5, each symptom will be scored daily by the subject as experienced 
during the past 24 hours. Also, subject will record the change of overall health and clinical 
outcomes as below.  
o In the past 24 hours, have you returned to your usual health  (before your COVID -
19 illness)? Yes or No  
o In the past 24 hours, have you returned to your usual activities (before your 
COVID -19 illness)? Yes or No  
o In the past 24 hours, what was the severity of your overall COVID -19-related 
symptoms at their worst? None, Mild, Moderate, or Severe  
o In the past 24 hours, have you been hospitalized ? Yes, No  
o In the past 24 hours, have you required home oxygen? Yes, No  
o In the past 24 hours, have you had any limitation on activities? Yes, No  
 
 
 
 
 
 
 
 
  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
85 
 Appendix 3  COVID -19: BASELINE SEVERITY CATEGORIZATION (Developing Drugs 
and Biological Products for Treatment or Prevention Guidance for Industry ) 
SARS -CoV -2 infection without symptoms  
• Positive testing by standard reverse transcription polymerase chain reaction (RT -PCR) assay or 
equivalent test  
• No symptoms  
Mild COVID -19  
• Positive testing by standard RT -PCR assay or equivalent test  
• Symptoms of mild illness with COVID -19 that cou ld include fever, cough, sore throat, malaise , 
headache, muscle pain, gastrointestinal symptoms, without shortness of breath or  dyspnea  
• No clinical signs indicative of Moderate, Severe, or Critical Severity  
Moderate COVID -19  
• Positive testing by stan dard RT -PCR assay or equivalent testing  
• Symptoms of moderate illness with COVID -19, which could include any symptom of mild illness 
or shortness of breath with exertion  
• Clinical signs suggestive of mod erate illness with COVID -19, such as respiratory rate ≥ 20 
breaths per minute, saturation of oxygen (SpO2) > 93% on room air at sea level, heart rate ≥ 90 
beats per minute  
• No clinical signs indicative of Severe or Critical Illness Severity  
Severe COVID -19  
• Positive testing by standard RT -PCR assay or an equivalent test  
• Symptoms suggestive of severe systemic illness with COVID -19, which could include any 
symptom of mod erate illness or shortness of breath at rest, or respiratory distress  
• Clinical  signs indicative of severe systemic illness with COVID -19, such as respiratory rate ≥ 30 
per minute, heart rate ≥ 125 per minute, SpO2 ≤ 93% on room air at sea level or PaO2/ FiO2 < 
300  
• No criteria for Critical Severity  
Critical COVID -19  
• Positive testing by standard RT -PCR assay or equivalent test  
• Evidence of critical illness, defined by at least one of the following:  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
86 
 - Respiratory failure defined based on resource utilization requiring at least one of the 
following:  
o Endotracheal intubation and mechanical ventilation, oxygen delivered by high - flow 
nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at 
flow rates > 20 L/min with fraction of delivered oxygen ≥ 0.5), noninvasive positive 
pressure ventilation, ECMO, or clinical diagnosis of  respiratory failure (i.e., clini cal 
need for one of the preceding therapies, but preceding therapies not able to be 
administered in setting of resource limitation)  
- Shock (defined by systolic blood pressure < 90 mm Hg, or diastolic blood pressure < 60 
mm Hg or requiring vasopressors)  
- Multi-organ dysfunction/failure  
NOTE: A clinical diagnosis of respiratory failure (in the setting of resource limitation) in which  
the management deviates from standard of care should be recorded as part of formal data  collection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
87 
 Appendix 4 Clinical Laboratory Parameters Collection Plan  
Test category  Local/Central  Test Name  
Hematology  
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Local  Hemoglobin  
Hematocrit  
Erythrocyte count (RBCs - Red Blood Cells)  
Leukocytes (WBCs - White Blood Cells)  
Differential  
Neutrophils, segmented  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  
Platelets  
 
  
 
Clinical Chemistry  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
Local   
Sodium  
Potassium  
Chloride  
Bicarbonate  
Total bilirubin  
Direct bilirubin  
Alkaline phosphatase (ALP)  
Alanine aminotransferase (ALT)  
Aspartate aminotransferase (AST)  
Gamma -glutamyl transferase (GGT)  
Blood urea nitrogen (BUN)  
Creatinine  
Creatine kinase (CK)  
Uric acid  
Total protein  
Albumin  
Calcium  
Phosphorus  
Glucose  
Amylase  
Lipase  
Lactate dehydrogenase (LDH)  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
88 
 Coagulation   
 
 
Local  International normalized ratio (INR), 
activated partial thromboplastin time(aPTT)  
Additional tests  
 
 
 
 
  
 
 
Local /Central * C-reactive protein (CRP); high -sensitivity  
Ferritin  
D-dimer  
Procalcitonin  
Troponin (preferably Troponin I )  
 
Virology  
  
 
Central  SARS -CoV -2 viral infection determination at 
screening -local  
SARS -CoV -2 viral load test  (quantitative RT -
PCR) —central  
Pharmacokinetic Analyses  
  
 
Central  Analyzed using validated LC -MS/MS methods 
with a LLOQ of approximately 5.00 ng/mL for 
GT0918  
Hormones(Male  &Female )  
 
Central  Testosterone  
 
Hormones(Female)   
 
Local  Serum P regnancy   
Urine Pregnancy  
* Central laboratories  will be used when it can’t be tested on local laboratory.  
 
 
 
 
 
  
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
89 
 Appendix 5. Subject Questionnaire  
1. What was the severity of your stuffy or runny nose at its worst over the last 24 hours?  
None  
=0 Mild  
=1 Moderate  
=2 Severe  
=3 
 
2. What was the severity of your sore throat at its worst over the last 24 hours?  
None  
=0 Mild  
=1 Moderate  
=2 Severe  
=3 
 
3. What was the severity of your shortness of breath (difficulty breathing) at its worst over the last 
24 hours?  
None  
=0 Mild  
=1 Moderate  
=2 Severe  
=3 
 
4. What was the severity of your cough at its worst over the last 24 hours?  
None  
=0 Mild  
=1 Moderate  
=2 Severe  
=3 
 
5. What was the severity of your Low energy or tiredness at its worst over the last 24 hours?  
None  
=0 Mild  
=1 Moderate  
=2 Severe  
=3 
 
 
6. What was the severity of your muscle or body aches at its worst over the last 24 hours?  
None  
=0 Mild  
=1 Moderate  
=2 Severe  
=3 
 
7. What was the severity of your headache at its worst over the last 24 hours?  
None  
=0 Mild  
=1 Moderate  
=2 Severe  
=3 
 
 
8. What was the severity of your chills or shivering at its worst over the last 24 hours?  
None  
=0 Mild  
=1 Moderate  
=2 Severe  
=3 
 
 
9. What was the severity of your feeling hot or feverish at its worst over the last 24 hours?  
None  
=0 Mild  
=1 Moderate  
=2 Severe  
=3 
 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
90 
 10. What was the severity of your Nausea (feeling like you wanted to throw up) at its worst over the 
last 24 hours?  
None  
=0 Mild  
=1 Moderate  
=2 Severe  
=3 
 
11. How many times did you vomit (throw up) in the last 24 hours?  
I did not vomit at all  
=0 1-2 times  
=1 3-4 times  
=2 5 or more times  
=3 
 
12. How many times did you have diarrhea (loose or watery stools) in the last 24 hours?  
I did not have 
diarrhea at all  
=0 1-2 times  
=1 3-4 times  
=2 5 or more times  
=3 
 
13. Rate your sense of smell in the last 24 hours:  
My sense of smell is 
THE SAME AS 
usual=0  My sense of smell is 
LESS THAN usual  
=1 I nave NO sense of 
smell  
=2 
 
14. Rate your sense of taste in the last 24 hours:  
My sense of taste is 
THE SAME AS 
usual=0  My sense of taste is 
LESS THAN usual  
=1 I have NO sense of 
taste  
=2 
 
 
Overall Covid -19-related Symptoms  
1. Overall, how bad are your symptoms TODAY (check one)?  
 
 
 
2. Overall, how is your general physical health today?  
 
 
 
3. Have you returned to your usual physical health (before your COVID -19 illness) (check  one)?  
 
 
4. Have you returned to your usual activities (before your COVID -19 illness) (check one)?  
 
 
 No 
symptoms  
☐ Mild  
☐ Moderate  
☐ Severe  
☐ 
Poor  
☐ Fair 
☐ Good  
☐ Excellent  
☐ 
Yes 
☐ No 
☐ 
Yes 
☐ No 
☐ 
  Suzhou Kintor Pharmaceuticals, Inc.                            Protocol # GT0918 -US-3001                      Confidential   
 
91 
 NIAID Daily Questions  
1. In the past 24 hours, have you been hospitalized?  
 
 
 
2. In the past 24 hours, have you required home oxygen?  
 
 
 
3. In the past 24 hours, have you had any limitation on your activities?  
 
 Yes 
☐ No 
☐ 
Yes 
☐ No 
☐ 
Yes 
☐ No 
☐ 